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 CHAPTER 1 INTRODUCTION 
 
1.1. Hepatocellular Carcinoma 
 
Primary liver cancer mainly refers to hepatocellular carcinoma (HCC), intrahepatic 
cholangiocarcinoma (ICC), and hepatic angiosarcoma(1). Hepatocellular carcinoma (HCC) 
accounts for 85% to 90% of primary liver cancers which ranks as the fifth most common 
malignancy worldwide and the third most common cause of cancer-related mortality(2).  
New Cases: An estimated 30,640 new cases of liver cancer (including intrahepatic bile 
duct cancers) are expected to occur in the US during 2013. More than 80% of these cases 
are hepatocellular carcinoma (HCC), originating from hepatocytes, the predominant liver 
cell type. Liver cancer incidence rates are three times higher in men than in women. From 
2005 to 2009, rates increased by 3.7% per year in men and by 3.0% per year in women(3).  
Deaths: An estimated 21,670 liver cancer deaths (6,780 women, 14,890 men) are expected 
in 2013. From 2005 to 2009, death rates for liver cancer increased by 2.3% per year in men 
and 1.3% per year in women(3).  
Risk factors: In the US and other western countries, alcohol-related cirrhosis, and possibly 
nonalcoholic fatty liver disease associated with obesity, account for the majority of liver 
cancer cases. Chronic infections with hepatitis B virus (HBV) and hepatitis C virus (HCV) 
are associated with less than half of liver cancer cases in the US, although they are the 
major risk factors for the disease worldwide. In the US, rates of HCC are higher in 
immigrants from areas where HBV is endemic, such as China, Southeast Asia, and sub-
Saharan Africa. Other risk factors for liver cancer, particularly in economically developing 
countries, include parasitic infections (schistosomiasis and liver flukes) and consumption 
of food contaminated with aflatoxin, a toxin produced by mold during the storage of 
agricultural products in a warm, humid environment(3).  
Pathogenesis: The exact pathophysiology of HCC is poorly understood .However 
alterations in molecular pathways involved in the process of HCC are depicted as 
follows:(a) activation of the Wnt/Frizzled/β-catenin pathway through mutations in β-
catenin as well as up-regulation of upstream elements, such as Frizzled receptors, (b) 
alteration of the MAPK signaling pathway through HBV or HCV infection, (c) activation 
of the JAK/STAT pathway through inactivation of JAK-binding proteins, (d) inactivation 
of the tumor suppressor gene p53 through gene mutation and posttranscriptional interaction 
with viral proteins as well as oxidative stress, (e) alteration of the tumor suppressor 
retinoblastoma (pRb Pathway) and p16INK4 genes through mutations or promoter 
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methylation and (f) alteration of the transforming growth factor-β pathway. So far, many 
HCC-related oncogenes, including AFP, RAS, c-FOS, c-JUN, RHO, TGF-a, HGF, 
CerbB2, HER-2, HER-2/neu, NEU, NGL, MDM2, MMP and IGF-β have been found. The 
abnormal expression of these genes with regard to a lasting cell proliferation results in 
carcinogenesis ultimately(4). Despite of deregulation of critical genes involve in cellular 
processes such as cell cycle control, apoptosis and cell migration, recent studies showed 
that molecules that regulate these events, including microRNAs (miRNAs) also play key 
role in development and progression of HCC(1, 5).  
Early detection: Screening for liver cancer has not been proven to improve survival. 
Nonetheless, many doctors in the US screen high-risk persons (e.g., HCV-infected persons 
with cirrhosis) with ultrasound or blood tests(3).  
Survival: The overall 5-year relative survival rate for patients with liver cancer is 15%. 
Forty percent of patients are diagnosed at an early stage, for which 5-year survival is 28%. 
Survival decreases to 10% and 3% for patients who are diagnosed at regional and distant 
stages of disease, respectively(3). 
1.1.1.  Treatment of HCC 
 
Early stage liver cancer can sometimes be successfully treated with surgery in patients with 
sufficient healthy liver tissue; liver transplantation may also be an option(3). Surgical treat-
ment of early stage liver cancer is often limited by the high frequency of tumor recurrence 
and metastasis after curative resection. Statistics show that the survival rate of patients who 
have had a resection is 30% to 40% at 5 years, postoperatively(4). Patients whose tumors 
cannot be surgically removed may choose ablation (tumor destruction) or embolization, a 
procedure that cuts off blood flow to the tumor(3). Chemotherapy and radiotherapy are the 
two other conventional therapies applied in the treatment of cancer, which also get an 
unfavorable score because of the resistance of HCC. Moreover, occurrence of HCC often 
coupled with liver dysfunction, leads to restrict the use of conventional chemotherapeutics 
as there is more or less non-selective toxicity with significant systemic side effects(6). 
Fewer treatment options exist for patients diagnosed at an advanced stage of the disease. 
Sorafenib (Nexavar) is a targeted drug approved for the treatment of HCC in patients who 
are not candidates for surgery(3). Sorafenib is a multi-kinase inhibitor that targets proteins 
of multiple signaling pathways simultaneously—VEGFR2, VEGFR3, PDGFR, Flt-3, c-kit 
and the Raf/MEK/ERK pathway—to inhibit tumor growth and to induce apoptosis of 
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tumor cells(5). In a phase III trial, patients with advanced HCC treated with the molecular 
targeted agent sorafenib, reported an increase in survival of approximately 3 months(7, 
8).Viral vectors, for example, recombinant adeno-associated virus (rAAV), mediated 
microRNAs targeted therapy which is targeting liver by hydrostatic pressure injection, is 
considered to be the appealing approach for liver disease as it is quite effective, associated 
with higher infectious rate and prolonged expression(4). 
1.2. microRNAs: Biogenesis, Processing and Function 
 
microRNAs (miRNAs) are a highly conserved group of endogenous small non-coding 
RNA (ncRNAs) molecules, which can be expressed in a tissue specific manner (9-11). 
miRNAs negatively regulate gene expression through binding of 6–8 nucleotide sequences 
(miRNA seed) to complementary sequences of target messenger RNA (mRNA), in the 
form of ribonucleoprotein complexes that mediate mRNA destabilization(12). In this way, 
they resulting in transcript degradation or translation inhibition(9-11). In the past 3 years, 
the number of microRNA loci annotated in miRBase has grown by approximately two-
thirds, from 15 172 loci in 142 species (release 16, October 2010) to 24 521 loci in 206 
species(release 20, June 2013)(13). Each miRNA can influence hundred of gene transcript 
and more than one miRNA can regulate any specific mRNA, which creates complexity in 
their capacity to modulate fundamental biological processes(14). 
From a historic standpoint, it is curious to note that miRNAs have long been discovered (in 
1993, by Victor Ambros et al.) before the 1998 Nature paper by Andrew Fire and Craig 
Mello, which introduced the term RNAi and was later rewarded with the Nobel prize (15, 
16). lin-4 was the first miRNA, discovered from C. elegans in 1993(16). Seven years later, 
the second miRNA let-7 was also discovered from C. elegans(17). This publication was 
certainly distinct and unique, as it suggested, for the first time, that small dsRNAs could 
play key roles in gene expression. In 2001, this kind of endogenous tiny non-protein 
coding single-stranded RNAs were first designated as “microRNAs” (18). Subsequently, 
more and more miRNAs were identified in many species ranging from plants to 
human(19).  
miRNAs are predicted to affect the expression of nearly 60% of protein-coding 
mammalian genes and thereby to control diverse cellular processes(20, 21). Fundamental 
changes at the cellular and organism level including development(22), aging(23), the stress 
response(24), cell proliferation(25) and apoptosis(26, 27), were shown to be regulated by 
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miRNAs. Furthermore, miRNAs have been implicated in various diseases, such as 
diabetes(28), cancer(29), hepatitis C(30), neuro-developmental(31) and mental (32) 
disorders. Rapidly growing knowledge of miRNAs as potent regulators in health and 
disease, makes miRNAs attractive as targets for therapeutic intervention(33, 34) as well as 
for diagnostic markers(35, 36). 
1.2.1. The Biogenesis of miRNAs and Target Recognition 
 
MicroRNAs are 20-23 nucleotides in length(10). In mammalian cells, miRNAs are 
typically transcribed by RNA polymerase II (exceptions: a few are manuscript of RNA 
polymerase III ) as long pri-miRNA molecules from intergenic regions of the genome, but 
may also be derived from intronic and exonic regions of coding and non-coding genes(12). 
The mechanism of transcriptional regulation of miRNAs is not fully determined, because 
identification of the miRNA promoters is still a challenging task(37). In the nucleus, 
canonical pri-miRNAs are capped with 7-methylguanosine and polyadenylated and 
cleaved by the RNAse III enzyme Drosha and its cofactor Pasha (or DGCR8)  to produce a 
60–100 nt precursor miRNA (pre-miRNA) hairpin molecule(38).  
RAN-GTP and exportin-5 complex, subsequently transport the pre-miRNAs into the 
cytoplasm. In cytoplasm, Dicer, also an RNAse III endonuclease, interacts with TRBP (Tar 
RNA Binding Protein) to mediate further processing of pre-miRNA to form a mature 20–
23 nt miRNA–miRNA* duplex(39). The duplex is unwound by a helicase and the mature 
miRNA is incorporated into effectors’ complex known as miRISC (miRNA induced 
silencing complex)(37, 40, 41), while the miRNA* (read as miRNA “star”) is degraded. 
The core components of miRISC are Argonaute proteins (AGO/EIF2C)(5) and 
GW182/TNRC6 protein families(42, 43). Within the RISC complex, miRNAs bind 
through imperfect base pairing to the 3’untranslated region (3’UTR) of target mRNAs(44). 
The binding specificity and efficiency is believed to be determined by 6–7 nucleotide 
sequence near 5′ region of miRNA. This sequence is called the “seed sequence” and is the 
initial binding site of the miRNA to the 3’UTR of the target mRNA(21). The subsequent 
procedures, depend on the degree of complementarily between the miRNAs and their 
targets. Imperfect complementarily of the miRNAs and the target mRNA, will cause 
translational repression of gene targets, while perfect matching, recruite  the CAF1–CCR4 
mRNA deadenylation complex to initiate mRNA degradation (40)(Figure 1.1). 
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Figure 1.1. MicroRNA biogenesis. MicroRNA (miRs) are encoded by sequences located within intergenic regions or 
embedded in intronic sequences throughout the genome and transcribed by RNA polymerase II (RNA pol II) to generate 
long primary miR transcripts(pri-miR). The hairpin structure of pri-miRs are cleaved by the Drosha or DiGeorge 
syndrome critical region 8 (DGCR8) complex to yield precursor miRs (pre-miR). The pre-miR translocates from the 
nucleous into the cytoplasm via exportin5/Ran-GTP, and is consequently processed by the Dicer/TARBP2 
(transactivation-responsive RNA-binding protein, also known as TRBP2) complex generating a miR:miR duplex. After 
unwinding and strand selection by unclear mechanisms, the mature miR is formed and loaded onto RISC (RNA-induced 
silencing complex) associated to Argonaute proteins (Ago1-4). The miR-RISC/Ago assembly complex can then target 
mRNAs through binding of the 3’-UTR (untranslated region) sequence or the mRNA open reading frame (ORF) which 
results in translation repression or mRNA degradation mediated possibly by Ago proteins(45). 
 
 
1.2.2. Functional and Genomic Organization of miRNAs 
 
Many miRNAs share the same seed sequence that is used in mRNA targeting. Four 
hundred twenty-six of the 1,112 mature and miRNA*s can be organized into sequence 
families(46). Two hundred ninety-nine of the 557 miRNA precursors can be organized into 
transcriptional units (cistrons, also known as genomic clusters). These cistronic miRNAs 
are typically located within 5 kb of each other in intergenic regions or within the same 
intron/exon and are co-transcribed and yield similar read counts for each member of a 
given miRNA precursor cluster(47). 
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1.2.3. Regulation of microRNA Expression  
 
Several mechanisms, including gene amplification, deletion, epigenetic alterations, and 
single-nucleotide substitution, have been implicated in altered miRNA expression(48). 
Yang et,al in 2011 reviewed regulation of microRNA expression and function by nuclear 
receptor signaling. Nuclear receptors (NRs) are ligand-activated transcription factors that 
regulate the expression of target genes by binding to cis-acting DNA sequences. Since 
miRNAs are encoded by genes that are mainly transcribed by RNA polymerase II, their 
transcription can be regulated by a variety of transcription factors including NRs. For 
example, ERα binds directly to the promoter region of miR-221/222 and recruits NCoR 
and SMRT to suppress miR-221/222 expression. Androgen receptor(AR) can also bind to 
the promoter region of miR-221 to repress miR-221 expression in LNCaP cells. AR is a 
ligand-dependent transcription factor that regulates the expression of androgen target 
genes(49).  
Post-transcriptional regulation has also been shown to essentially influence miRNA 
turnover rate or inhibitory activity. The 3′ end of mature miRNA can further be subject to a 
series of additional modifications such as uridylation that blocks Dicer processing and 
induces miRNA degradation and adenylation that affects miRNA stabilization. On the 
other hand in plants, 2′-O-methylation protects miRNA from uridylation, decay, and 
miRNA editing that makes an adenosine to inosine conversion resulting in altered mRNA 
target specificity. miRNAs expression can be dynamically regulated under certain 
conditions. For example, under inflammatory conditions, KH-type splicing regulatory 
protein (KSRP) can promote miR-155 maturation through binding to the terminal loop of 
pre-miRNA. In addition, expression of Dicer can be suppressed upon activation of various 
stress pathways, suggesting an implication of stress in alteration of miRNA expression(50).  
It has been demonstrated that the infection of Epstein-Barr virus (EBV) could influence 
human cellular miRNA expression. Godshalk et al. found that 99.5% of tested miRNAs 
displayed an average down-regulation of 19.92-fold upon initial EBV infection of primary 
cultured human B-cells, suggesting an activation of global suppression of miRNA-
generating machinery(51). 
Taken together, the growing body of literature has indicated that the miRNA biogenesis 
and its expression regulation are highly complicated, requiring participation of multiple 
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layers of transcriptional and post-transcriptional modifications and subject to tight and 
dynamic control under distinct physiological and pathological conditions(50). 
 
1.3. microRNA and Cancer 
 
Dysregulated miRNA expression is a common feature of solid and hematopoietic 
malignancies(52). The first demonstration of the link between miRNAs and cancer was 
reported in 2002 by Calin et al(52). They found that miR-15 and miR-16 are involved in 
the pathogenesis of chronic lymphocytic leukemia(CLL). Their evidence that suggests a 
role of tumor suppressor for miRNAs supported by the observation of down-regulation of 
miR-15a and miR-16–1 in two CLL patients(52-54). A study by Cimmino et al. in 2005, 
showed that miR-15a and miR-16–1 act as tumor suppressors by down-regulating B-cell 
CLL/lymphoma 2 (BCL2), a gene that is frequently up-regulated in CLL(55). Therefore, 
down-regulation of miR-15a and miR-16–1, which is mainly due to a genetic deletion, 
might promote B-cell proliferation in CLL (56). 
Following, Several groups have studied the miRNA expression in cancer patients and 
found that miRNAs are differentially expressed in normal versus tumor tissues in different 
cancer types including leukemia(53), lymphoma(57), glioblastoma(58, 59), 
neuroblastoma(60), papillary thyroid carcinoma(61, 62), lung(63), breast(64, 65), liver 
(30), pancreas(66), gastric(35), colorectal(27, 67), ovarian(68), prostate(64, 69, 70), kidney 
and bladder cancer(71). Such researches revealed the aberration expression of miRNAs 
during carcinogenesis. The first report of miRNA deregulation in solid tumors was the 
observation of a consistent down-regulation of miR-143 and miR-145 in colorectal 
cancer(72). In the case of Lung cancer a reduction of >80% of let-7 expression was found 
by northern blotting in 44% (7 out of 16) of patients compared with healthy controls. 
Consequently many researches showed that profiles of miRNA expression are highly 
informative for tumor classification, prognosis, and response to therapy. Lu et al. at 2005 
showed that miRNA expression profiles can be used in cancer diagnosis and human cancer 
classification(73).  
In 2005, three reports provided the first mechanistic insight into how miRNAs might 
contribute to carcinogenesis. Two independent reports illustrated an interaction between 
miR-17-92 cluster and Myc(74, 75), and the third one uncovered the regulation of Ras by 
let-7(76). Lee et al showed that miRNA precursor processing reduce in cancer cells 
compared to normal human cell lines and tissues(77). Also miRNA processing 
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machineries, Drosha and Dicer, have a decreased expression in cancer cells. In ovarian 
cancer cases, the reduction of Dicer and Drosha correlates with a poor prognosis, 
suboptimal surgical cytoreduction and an advanced tumor stages(78). 
1.3.1. miRNAs as Oncogenes or Tumor Suppressor Genes 
 
There are strong evidences that miRNAs can function as tumor suppressors (anti-
oncomiRs) or tumor promoters (oncomiRs)(56). miRNAs are often down-regulated in 
cancerous tissues and target oncogenic proteins. They are classified as tumor suppressor 
miRNAs(79). Let-7 is widely viewed as a tumor suppressor miRNA. Consistent with this 
activity, the expression of let-7 family members is down-regulated in many cancer types 
when compared to normal tissue and during tumor progression(80). Moreover many 
human let-7 genes, map to regions altered or deleted in human tumors, indicating that these 
genes may function as tumor suppressors(25). Takamizawa et. al. observed that 
postoperative survival time in lung cancer patients directly correlated with let-7 expression 
levels: patients with lower let-7 expression survived for less time than those with higher 
let-7 expression(81). Development of spontaneous tumors induced by deletion of a single 
miRNA, miR-122, in the liver indicates that this miRNA indeed functions as a tumor 
suppressor. MiR-122, the most abundant miRNA in liver, was first suggested as a tumor 
suppressor in liver due to its diminished expression in primary HCCs of human and rodent 
origin, and its ectopic expression studies in HCC cell lines and xenograft models(31, 32). 
Loss of miR-122 results in the up-regulation of its target genes, including Adam10/17, 
Igf1R, Srf, and Ccng1, and inhibits tumorigenic properties of HCC cells(32). Similarly 
down-regulation of miR-199a-3p that abundantly expressed in the liver, induces ERK 
signaling pathway partly through targeting PAK4(82). Moreover Dramatic tumor 
suppression by the adeno-associated viral delivery of miR-26a in a Myc driven mouse 
model of HCC suggests that miR-26a may inhibit tumor growth by directly targeting genes 
involved in the control of cell cycle, such as Ccnd2 and Ccne2(34).  
However, microarray analysis has identified that there is an increase in some miRNAs in 
tumor tissues compared to normal tissues. miRNAs with increased expression in the tumor 
,often target tumor suppressors, are considered as "oncomiRs"(79, 83). The OncomiRs 
promote tumor development by negatively inhibiting tumor suppressor genes and/or genes 
that control cell differentiation or apoptosis. OncomiRs are significantly over-expressed in 
various tumors because of gene amplification, epigenetic mechanisms or transcriptional 
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dysregulation(84). miR-17-92 cluster is a typical example, which is located at chromosome 
13q31, a region amplified in lung and other malignancies(84). Myc-induced up-regulation 
of miR-17-92 cluster has been shown to enhance tumorigenesis and angiogenesis(85). 
Recent studies also revealed that miR-17-92 was up-regulated in sonic hedgehog-driven 
medulloblastomas and induced by N-myc in sonic hedgehog-treated cerebellar neural 
precursors(86). Among others oncogenic miRNAs, miR-21 which is widely up-regulated in 
different types of cancers has been shown to promote tumor growth by targeting 
phosphatase and tensin homolog (PTEN). PTEN is an important tumor suppressor that is 
involved in control of cell migration and invasion by inhibiting its downstream targets 
including FAK, MMP2 and MMP9(36). Also in breast cancer cells, silencing of miR-21 
inhibited cell growth in vitro and in vivo by causing down-regulation of Bcl-2 and 
induction of apoptosis(87). 
 miRNA expression profiling have reported increased expression of miR-155 in various 
cancers. It’s expression was significantly correlated with poor survival in pancreatic cancer 
patients(88). In another study, transfection of antimiR-155 oligonucleotides into pancreatic 
cancer induced the expression of tumor suppressor protein 53-induced nuclear protein 1 
(TP53INP1) and enhanced apoptosis(89).  
Furthermore, in a choline-deficient and amino-acid-defined (CDAA) diet-induced HCC 
model, many oncogenic miRNAs, including miR-155, miR-221/222, miR-21 and miR-
181b/d, were up-regulated at an early stage of hepatocarcinogenesis(40-43). Interestingly, 
these miRs were reported to target tissue inhibitor of metalloprotease 3 (TIMP3)(40, 42, 
43), which is involved in tumor invasion and metastasis as PTEN(37). miR-372 and miR-
373 are two additional examples of oncogenic miRNAs that are shown to promote cell 
proliferation and tumor development by neutralizing p53-mediated CDK inhibition, 
possibly through direct targeting of the tumor suppressor gene LATS2. Further research is 
likely to add many more miRNAs to the growing list of oncomiRs(90). 
1.3.1.1. miRNA-221: Its Role in Tumor Progression 
miR-221 is a highly homologous miRNAs ,located in an intergenic region at chromosome 
Xp11. Sequence location Starts at 45605585 and ends at 45605694bp from pter (according 
to hg19-Feb_2009). miR-221 encoded along with miR-222 in cluster, containing identical 
seed sequences and both map to the X chromosome separated by 727 bases. In general, the 
microRNA genes are transcribed by RNA polymerase II, whereas RNA polymerase III is 
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also responsible for transcription of some other microRNAs. It is not known which RNA 
polymerase transcribes miR-221/miR-222. miR-221 and miR-222 were shown to be 
expressed as a single pri-microRNA transcript in c-kit positive HUVEC cells. In the 
following Pre-microRNA221 (Accession: MI0000298) with 110bp length has been formed 
and finally processed to 23 base pair mature miR-221 (Accession: MIMAT0000278)(91). 
 Regulation of miR-221 
 
Regulation of miR-221 has been investigated in rare research. In neuroblastoma miR-221 
was shown to induced by MYCN. Given that MYCN is a major regulator of neuroblastoma 
tumor biology, Schulte et al in 2008 investigated if specific miRNAs are regulated by the 
MYCN transcription factor in neuroblastoma cells. Using a miRNA microarray containing 
384 different miRNAs and a set of 160 miRNA real-time PCR assays to validate the 
microarray results, they showed  the role of MYCN in regulation of 7 miRNA including 
miR-221.  Additionally, they  reported miRNA induction to be a new mechanism of gene 
expression down-regulation by MYCN(60). Santhekadur et al in 2012 unraveled a linear 
pathway in which Staphylococcal nuclease domain-containing 1 (SND1)-induced 
activation of NF-_B resulted in induction of miR-221 and subsequent induction of 
angiogenic factors Angiogenin and CXCL16. CXCL16 can be induced by TNFβ treatment 
via NF-_B activation, and both CXCL16 and angiogenin activate NF-_B, thus establishing 
a positive feedback regulation. Both CXCL16 and angiogenin activate Akt/mTOR 
signaling, which in turn is involved in CXCL16 and angiogenin expression and secretion. 
On the other hand, miR-221 targets phosphatase and tensin homolog (PTEN) and DDIT4, 
inhibitors of the Akt/mTOR pathway. Thus, an expansive protumorigenic signaling 
network lies downstream of SND1(92). 
 
 miR-221 in Tumorogenesis 
 
Many studies to date have been reported on the role of miR-221/222 in cancer 
development either as oncomiR or as tumor suppressors-miRs (anti-oncomiRs ) which 
summarized in  Table 1.1 and  1.2. The two studies that evidenced a tumor suppressive role 
for miR-221/222 in OTSCC and erythrocytes, indicating that microRNA function is 
exclusively dependent on the cellular contest and tumor type(93). In Luminal Breast 
Cancer , most high-grade tumors express low levels of miR-221/222(94). The roles of 
 CHAPTER 1 INTRODUCTION 
 
miR-221/222 in cellular signaling pathways as an oncomiR or onco-suppressor-miR 
depicted in Figure 1.2 and 1.3. These findings provide evidence that a single miRNA, 
through its ability to modulate different genes that  involved in the same network, may act 
as a strong inhibitor of the entire cellular pathway, suggesting a possible greater 
therapeutic potential for miRNAs than for a single gene(93). 
 
Table 00.1.miR-221/222as oncogene 
miRNA Target Deregulation in Cancer 
P27/Kip1 Giloblastoma, thyroid papillary carcinomas, hepatocellular carcinoma, breast, 
prostate and pancreatic cancer(95-100) 
P57 Hepatocellular carcinoma(99, 100) 
Puma Glioblastoma(101) 
ER-α FOXO3 Breast(102) 
PTEN TIMP3 NSCLC, Hepatocarcinoma, giloma, gastric canser(100) 
DDIT4 Hepatocellular carcinoma(103) 
Bim Prostate cancer(104) 
 
 
Table 1.2.miR-221/222 as tumor suppressor genes 
miRNA Target Deregulation in Cancer 
SODI MMP1 tongue squamous cell carcinoma (OTSCC)(105) 
c-Kit erythrocytes(106) 
α6β4 integrin luminal breast cancer(94) 
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Figure 1.2.MiR-221/222 as oncomiRs MiR-221/222 act as oncomiRs by targeting important tumor suppressor genes 
such as PTEN, TIMP3, p27Kip1, p57, Bim. MiR-221/222 over-expression induces cell proliferation through the 
activation of cell cycle and the Akt pathway and blocks TRAIL-induced apoptosis. Moreover, miR-221/222 determine 
fulvestrant resistance through the activation of the β-catenin pathway(93) 
Figura 1.3. MiR-221/222 as tumor suppressor miRs.MiR-221/222 act as tumor suppressor miRs in the 
erythropoietic lineage cells, and oral tongue squamous cells by targeting c-Kit, matrix metalloproteinase 1 
(MMP1) and manganese superoxide dismutase (SOD2) (93). 
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Almost all of the proposed target genes of miR-221 are associated with hallmark of cellular 
processes that characterized in cancer cells. miR-221 impairs apoptosis and induces cell 
proliferation in different types of cancer cells(93). These functional changes occur because 
miR-221 is capable of targeting and down-regulating known tumor suppressors; including 
p27Kip1, p57Kip2(70, 107), phosphatase, tensin homolog(PTEN)(107, 108), a tissue 
inhibitor of metalloproteinase-3(100), and the DNA damage-inducible transcript 4 
(DDIT4)(103), a modulator of the mTOR pathway and p53 up-regulated modulator of 
apoptosis (PUMA)(107), a Bcl-2 homology 3 (BH3)-only Bcl-2 family member and a 
critical mediator of p53-dependent and p53-independent apoptosis. 
Functional studies by Medina et al showed that miR-221 and miR-222 prevent quiescence 
when elevated during growth factor deprivation and induce precocious S-phase entry, 
thereby triggering cell death(109). Thus, the physiologic up-regulation of miR-221 and 
miR-222 is tightly linked to a cell cycle checkpoint that ensures cell survival by 
coordinating competency for initiation of S phase with growth factor signaling pathways 
that stimulate cell proliferation. 
Gene expression profiling of miR-221-transfected-SNU-398 cells was analyzed by 
Negrini’s research group in 2013. This analysis revealed that enforced expression of miR-
221 in SNU-398 cells caused the down-regulation of 602 mRNAs carrying sequences 
homologous to miR-221 seed sequence within their 3_UTRs. Pathways analysis performed 
on these genes revealed their prominent involvement in cell proliferation and apoptosis. 
Activation of E2F ,MYC ,NF-kB ,and β-catenin pathways was experimentally proven. 
Some of the new miR-221 target genes, including RB1, WEE1(cell cycle 
inhibitors),APAF1(pro-apoptotic),ANXA1,CTCF (transcriptional repressor) , were 
individually validated as miR-221 targets in SNU-398, HepG2, and HEK293 cell 
lines(110).  Regard to their inhibition of RB1 expression , levels of miR-221/222 appear to 
be major factors in cell-cycle control(111).  
Yang et al (2014) showed a  negative correlation between miR-221 or miR-222 and 
SIRT1(Sirtuin Histone Deacetylase SIRT1), but no direct target relationship was identified. 
Inhibition of miR-221 or miR-222 leads to reduced cell proliferation and migration and 
increased apoptosis in prostate cancer cells. These effects showed potentially mediated by 
up-regulation of SIRT1(112). 
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1.3.1.2. miR-199a: Its Role in Tumor Progression 
miR-199 has been shown to be a vertebrate specific miR family that emerge at the origin of 
the vertebrate lineage. In 2003, two mature forms derived from the same precursor, miR-
199-s (from the 5’ half) and miR-199-a (from the 3’ half), were cloned from human 
osteoblast sarcoma cells and mouse skin, respectively(113). Expression of the microRNA 
was validated in zebrafish, and its ends mapped by cloning. The two microRNA sequences 
were named miR-199a and miR-199a* (from the 3’ arm), respectively. Later it was shown 
that both mature forms are expressed in humans, and it was renamed miR-199a-5p and 
miR-199a-3p, respectively(114). There are two loci that encode the precursor of miR-
199a-5p and -3p in the human genome; one is on Chromosome 1(miR-199a-2, miRBase 
Accession MI0000281) and the other on Chromosome 19 (miR-199a-1, miRBase 
Accession MI0000242)(114, 115). 
miR-199a-1 located on Chromosome 19 (Chr19) is embedded in the anti-sense strand of 
intron 15 of Dynamin 2 (DNM2), whereas miR-199a-2 located on Chromosome 1 (Chr1) 
is embedded in the anti-sense strand of intron 14 of Dynamin 3 (DNM3). 
Within Dynamin3 gene (Dnm3), miR-199a is associated with miR-214 and both miRs are 
transcribed together as a common primary transcript, demonstrated in mouse, human and 
zebrafish(116). The biological significance of the co-expression of miR-199a and miR-214 
was revealed recently(115). it suggested that TP53 was activated by miR-214 and 
participated in the positive regulation of miR-199a/miR-214 via repressing DNMT1(Figure 
1.4.). DNMT1 is primarily responsible for the maintenance, while DNMT3A and 
DNMT3B (de novo methyltransferases) are responsible for the establishment of genome 
DNA methylation patterns(115). 
 
 
 
 
 
 
 
 
 
 Figure 1.4. diagram describes the miR-199a/miR-214 self-regulatory network via TP53 and 
DNMT1 in TGCT(133). 
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There is no evidence of functional correlation between the expression of the dynamin 
genes and the miR-199a precursors: this may be due to the fact that the expression of the 
miRNA precursors is controlled by their own promoters. 
 
 Regulation of miR-199a 
 
Currently, two mechanisms that control the expression of miR-199a have been discovered. 
One is the regulation by transcription factors TWIST1 and EGR1 on Chr1; the other is the 
methylation status of miR-199a promoters on both Chr1 and Chr19. Studies in several cell 
lines showed that both promoter regions on Chr1 and Chr19 were hypermethylated (higher 
than 90%) in cancer cells but hypo- or not methylated in normal fibroblasts. 
Correspondingly the expression of miR-199a was higher in normal fibroblasts than cancer 
cells(117). Genome-wide DNA methylation profiling revealed that the promoter region of 
miR-199a-2 on Chr1 was hypermethylated in testicular germ cell tumors compared to the 
hypomethylation status in normal testicular fibroblasts. Apparently hypermethylation in 
testicular cancer cells caused severely reduced expression of miR-199a(118). Similar 
observations were made in non-small cell lung cancer, colorectal cancer and breast cancer 
cell lines (119). 
Besides TWIST1, EGR1, and DNA methylation, other factors have been reported to 
control expression of miR-199a. Reduced expression of miR-199a-3p in hepatocellular 
carcinoma was shown to be mediated by histone modification and was independent of 
DNA methylation(120). In vitro cell model studies of liver injury and fibrosis showed that 
farnesoid X receptor (FXR) could negatively regulate miR-199a-3p at the post-
transcriptional level(121). In mice cardiac myocytes, miR-199a-5p was upregulated during 
cardiac hypertrophy via β-adrenergic receptor (β-AR) stimulation, but downregulated by 
AKT activation during hypoxia (122). Another transcription factor, signal transducer and 
activation of transcription 3 (STAT3) was demonstrated to negatively regulate miR-199a-2 
by suppressing its promoter activity in mice cardiocytes (123).  
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 miR-199a in Tumorigenesis 
 
miR-199a has been shown to be implicated in a wide variety of cellular and developmental 
mechanisms such as various cancer development and progression, cardiomyocytes 
protection or skeletal formation(114).  
During tumorigenesis, depending on the nature of the cancer, miR-199a, especially its -3p 
mature form, may act as either a potential tumor suppressor (anti-oncomiR) or an oncogene 
(OncomiR) (Table 1.3.). 
 
 miR-199a as Anti-oncomiRs 
 
MiR-199a was frequently down-regulated in human hepatocellular carcinoma (HCC)(124). 
HIF-1α was identified as a direct target. MiR-199a through targeting of HIF-1α could 
inhibit cell proliferation , as it shown in virto and in vivo studies(125). Another study in 
HCC showed that miR-199a-3p could target tumor-promoting PAK4 to suppress HCC 
growth through inhibiting the PAK4/RAF/MEK/ERK pathway both in vitro and in 
vivo(120). CD44+(126), pro-invasion molecule DDR1(127) and mTOR(128) has been 
shown as other targets of miR-199a in HCC. 
Aside from the down regulation in HCC, In serous ovarian cancer patient tissues, miR-
199a was down-regulated and significantly correlated with a poor prognosis. In 
osteosarcoma, miR-199a-3p showed  reduced expression(129). Which affecting 
proliferation, migration and cell cycle progression. Molecules that were affected and which 
might be targets of miR-199a-3p include MET, mTOR and STAT3(130). Peng et al (2013) 
suggested that miRNA-199a-3p is associated with human gastric cancer through its ability 
to decrease cancer cell proliferation and target the mTOR signaling pathway(131). 
Similarly,  Wu et al in 2013 reported that microRNA-199a-3p regulates endometrial cancer 
cell proliferation by targeting mammalian target of rapamycin (mTOR)(132). Using 
microarray and immunoblotting analyses it has been shown that miR-199a* targets 
the Met proto-oncogene(117).  
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Table 1.3.miR-199a regulation and function in human cancer 
Cancer miR-199a Expression miR-199a Involved 
Biological Processes 
Validated Targets # 
Renal cell cancer Down-regulated in RCC cells and tissues  GSK-3β (protein 
only) 
Gastric cancer miR-199a-3p up-regulated in patients with 
recurrence, 
miR-199a up-regulated in gastric 
cancer/metastatic 
tissues/Japanese gastric cancer tissues 
Promotes proliferation 
and metastasis, 
progression-related 
MAP3K11 (protein 
only) 
Biliary tract 
cancer 
miR-199a-3p up-regulated during malignancy   
HCC miR-199a down-regulated Anti-proliferation, 
anti-growth of HCC, 
PAK4/Raf/MEK/ERK 
pathway, anti-invasion 
modulator of cell cycle 
HIF-1α (protein), 
PAK4 (protein), 
CD44 (mRNA), 
DDR1(mRNA), 
mTOR (mRNA) 
Osteosarcoma miR-199a down-regulated in cells and tissues Anti-proliferation, 
anti-migration and 
affect cell cycle 
MET? mTOR? 
STAT3? 
Esophageal 
adenocarcinoma 
miR-199a-3p and -5p up-regulated in worse 
survival patients 
  
Testicular germ 
cell tumors 
miR-199a-3p and -5p down-regulated in cells 
and tissues 
anti-invasion, anti-
migration,anti-
proliferation 
PODXL (mRNA) 
Breast Cancer  miR-199a down-regulated in tissues   
Ovarian cancer miR-199a-2 up-regulated in ovarian cancer stem 
cells; 
miR-199a down-regulated in serous ovarian 
cancer 
IKKβ/NFκB pathway, 
 
IKKβ (protein) 
Melanoma miR-199a up-regulated in older adults (>60) TLR-MyD88-NFκB  
Bladder cancer  down-regulated in cells and tissues Tumor miR-199a-3p suppressive KRT7 (mRNA) 
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 miR-199a as OncomiRs 
 
Comparing two sets of acute myeloid leukemia (AML) patients, miR-199a was expressed 
much higher in patients with worse overall and event-free survival. High expression of 
miR-199a was also identified in AML patients with isolated trisomy 8. Chen et al showed 
that the property of ovarian cancer cells to enhance the inflammatory microenvironment as 
a result of the expression of an active IKKβ pathway. They identified that  miR-199a-2 due 
to stimulation by TWIST1 down regulated IKKβ, shut down the IKKβ/NFκB 
pathway(133). Lijun et al  identified a dramatically up-regulated microRNA, miR-199a-5p, 
in ADPKD(Autosomal Dominant Polycystic Kidney Disease) tissues and cell lines. Their 
data show that inhibition of miR-199a-5p suppressed cyst cells proliferation and induced 
cell apoptosis. We found that miR-199a-5p might exert this effect through targeting 
CDKN1C/p57(134). 
Summary of key factors relating to miR-199a and its functions on different targets 
illustrated in Figure 1.5. 
 
 
 
 
 
Figure 1.5. key factors relating to miR-199a function(114). 
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1.4.  microRNAs in Liver Health and Diseases 
 
1.4.1. The  Role of miRNAs in Liver Development 
 
MicroRNAs fine-tune all physiological and many pathological processes that are 
fundamental to normal liver functions as well as liver diseases. In the liver miRNAs 
regulate various cellular processes like inflammation, fibrosis, lipid and glucose 
metabolism(14). lin-4 and let-7, two miRNAs identified in C. elegans, are critical 
components to regulate different stages of development in C. elegans(135). However, its 
role in liver development has not been addressed because two studies that have reported 
phenotype of liver-specific Dicer 1 knockout mice used Alb-Cre mice where the gene is 
deleted after the development of the liver bud(136). Crossing Dicer 1 floxed mice to Afp-
Cre or Foxa3-Cre may be helpful to address the role of miRNAs in liver development. 
Shu-hao Hsu et al have established essential role of miR-122 the most abundant, highly 
conserved, liver-specific miRNA in maintaining the differentiation state of the liver, since 
its loss induced proliferation of oval and bile duct cells in young adult mice and 
hepatocellular carcinoma HCC with age(137). In addition to miR-122, several other 
miRNAs appear to be involved in liver differentiation like miR-30a which its knockdown, 
results in defects in the intrahepatic bile duct in zebrafish and miR-23b which governs 
differentiation of hepatocytes and cholangiocytes by silencing Smad 3, 4 and 5. Many 
studies have revealed differential expression of miRNAs between embryonic and adult 
livers and correlated these findings with the critical factors involved in liver development. 
However, the expression of miRNA which is often observed in the total liver RNA, may 
not reflect the actual biological role of differentially expressed miRNA in specific cell 
types. Therefore, it is necessary to analyze the miRNA expression at different stages of 
liver development by monitoring their expression in specific cell types. Also, in absence of 
knockout animal models, it is difficult to pinpoint the developmental role of these 
miRs(37).
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1.4.2. Involvement of Specific miRNAs in HCC 
 
It has been well established that dysregulation in miRNAs is associated with liver diseases 
such as hepatocellular carcinoma(14). Pineue et al profiled miRNA expression in tissue 
samples (104 HCC, 90 adjacent cirrhotic livers, 21 normal livers) as well as in 35 HCC cell 
lines. They revealed set of 12 miRNAs (including miR-21, miR-221/222, miR-34a, miR-
519a, miR-93, miR-96, and let-7c) was linked to disease progression from normal liver 
through cirrhosis to full-blown HCC and had the highest diagnostic value(103). 
Some other studies have been revealed that specific miRNAs modulate various cellular 
processes in the liver and their aberrant expression correlates with the severity and poor 
prognosis of HCC. In one study, the expression of miR-199a, miR-92, miR-106a, miR-
222, miR-17-5p, miR-18 and miR-20 correlated with the degree of tumor differentiation, 
suggesting the involvement of these miRNAs in HCC progression(138). 
 miRNA-122, an abundant liver-specific miRNA that modulates hepatic lipid 
metabolism(139), is often down-regulated in human HCC(140). Loss of expression of 
miR-21 correlates with loss of mitochondrial metabolic function that negatively affect on 
critical liver function, thereby contributing to the morbidity and mortality of liver cancer 
patients(141).  
Examination of miRNAs in HCC with cirrhotic background revealed that members of the 
let-7 family and miR-145 were down-regulated(142). In these tissues and in HCC cell 
lines, miR-122 was also down-regulated, and its target gene product, cyclin G1, was highly 
expressed, promoting the growth of cancer cells(142). Other studies have shown that 
miRNAs associated with cell cycle inhibition (miR-34a, miR-101, miR-199-a-5p and miR-
223) were down-regulated in HCC(143) , and those involved in cell proliferation and 
inhibition of apoptosis (miR-17-92 polycistron, miR-21, miR-96, miR-221 and miR-224) 
were up-regulated(99, 144-146). Furthermore, miRNA-221 is associated with tumor 
multifocality(147).  
As demonstrated in other examples (Table 1.4 and Figure 1.6), aberrant miRNA expression 
leads to the dysregulation of critical cellular mechanisms and activation of tumorigenic 
pathways involved in tumor differentiation, diagnosis, staging, progression, prognosis and 
response to therapy(139-143, 148-152). 
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Figure 1.6: Summary of deregulated miRNAs identified in different liver disease. The arrow indicates 
the abnormal expression pattern of each miRNA in the designated disease. Red, up-regulated; Green, down-
regulated(37). 
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Table 1.4. Differentially expressed miRNAs in liver tissues and hepatocellular carcinoma (HCC) 
 
Sample type Methods miRNA* Cellular 
target/Mechanism 
References 
Tumor tissue 
 
 
 
 
Tumor tissues, rat 
model of hepatoma  
 
 
Tumor tissue  
 
 
HCC cell lines  
 
Tumor tissues,  
HCC cell lines  
 
HCC cell lines  
 
 
 
 
Tumor tissues, HCC 
cell lines  
 
Tumor tissues, HCC 
cell lines  
 
Tumor tissues  
 
Human and 
Woodchuck HCC 
cell lines  
 
Tumor tissues  
 
 
Tumor tissues  
 
 
Tumor tissues 
Microarray,qPCR 
 
 
 
 
Microarray,  
Northern blot  
 
 
Microarray  
 
 
qPCR  
 
Microarray, qPCR  
Northern blot  
 
Western blot, Soft 
agar assay  
 
 
 
qPCR, Western blot  
 
 
Microarray, Northern 
blot, Western blot  
 
Microarray, qPCR  
 
qPCR, Northern blot  
 
 
 
qPCR, Northern blot  
 
 
Microarray, qPCR, 
Northern blot  
 
Microarray  
miR-199a, miR-92,  
miR-106a, miR-222,  
miR-17-5p, miR-18,  
miR-20  
 
miR-122, let-7a, miR-
21, miR-23, miR-130, 
miR-190, miR-17-92 
family  
 
miR-122  
 
 
miR-122  
 
miR-122  
let-7 family, miR-145  
 
miR-122  
 
 
 
 
miR-34a  
 
 
miR-101  
 
 
miR-199-a-5p, miR-223  
 
miR-17-92, miR-21  
 
 
 
miR-221  
 
 
miR-21  
 
miR-224  
Tumor progression  
 
 
 
 
Tumorigenesis  
 
 
 
Loss of mitochondrial 
metabolism  
 
NDRG3  
 
Cyclin G1  
 
 
ADAM17, migration, 
invasion, anchorage-
dependence, 
angiogenesis, 
metastasis  
 
c-Met, apoptosis, cell 
cycle arrest, 
senescence 
  
Mcl-1, apoptosis, 
tumor suppression  
 
Cell cycle inhibition  
 
Cell proliferation, 
apoptosis  
 
 
CDKN1C/p57, 
CDKN1B/p27  
PTEN  
 
Apoptosis inhibitor-5  
(138) 
 
 
 
 
(148) 
 
 
 
(141) 
 
 
(149) 
 
(142) 
 
 
(150) 
 
 
 
 
 
(151) 
 
 
 
(153) 
 
 
(143) 
 
(144) 
 
 
 
(99) 
 
 
(145) 
 
(146) 
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1.4.3. microRNA-221 and HCC 
 
Highly expression of miR-221 has been described as part of a cancer signature in human 
hepatocellular carcinoma (HCC) and its targeting by tailored treatments has been proposed. 
(124). The evidence supporting the role of miR-221 in HCC has been mainly focused on 
the discovery of miR-221 targets as well as on its possible therapeutic exploitations. 
Negrini in 2008 showed over-expression of miR-221 cause down-regulation of 
CDKN1B/p27 and CDKN1C/p57, known inhibitors of the cell cycle, indicating a reverse 
relation between their expressions in HCC. Down-regulation of both CDKN1B/p27 and 
CDKN1C/p57 occurred in response to miR-221 transfection into HCC derived cells and a 
significant up-regulation of both CDKN1B/p27 and CDKN1C/p57 occurs in response to 
antimiR-221 transfection. Also they proved that through controlling these two CDKIs, up-
regulation of miR-221 can promote growth of HCC cells by increasing the number of cells 
in S-phase. Moreover the relevance of these studies in primary tumors matched HCC and 
cirrhosis samples were assayed for miR-221 as well as for CDKN1B/p27 and 
CDKN1C/p57 expression. They showed that MiR-221 was up-regulated in 71% of HCCs 
cases, whereas CDKN1B/p27 and CDKN1C/p57 proteins were down-regulated in 77% of 
cases. Significantly, the observed down-regulation of CDKIs were not present at the RNA 
level, indicating that the protein down-regulation was post-transcriptionally regulated. No 
association was found between miR-221 levels and the causes of underlying liver disease, 
in particular with viral infections, gender, histopathological grading and a-fetoprotein 
levels. So they proved In vivo regulation of CDKN1B/p27 and CDKN1C/p57 by miR-221 
and suggested that miR-221 has an oncogenic function in hepatocarcinogenesis by 
targeting CDKN1B/p27 and CDKN1C/p57, hence promoting proliferation by controlling 
cell-cycle inhibitors(99). Negrini et al in 2009 showed that miR-221 also targets Bmf, a 
pro-apoptotic BH3-only protein and inhibits apoptosis of HCC cells. The analysis of HCC 
tissues revealed an inverse correlation between miR-221 and Bmf expression and a direct 
correlation between Bmf and activated caspase-3, as a marker of apoptosis. They also 
showed that high miR-221 levels were associated with tumor multifocality and reduced 
time to recurrence after surgery(147). miR-221 targets other tumor suppressors including 
phosphatase and tensin homolog, a tissue inhibitor of metalloproteinase-3(100), and the 
DNA damage-inducible transcript 4 (DDIT4), a modulator of the mTOR pathway(103) in 
HCC. Almost all of the proposed target genes are associated with hallmark cellular 
processes that characterize liver cancer cells: apoptotic resistance, increased cell growth 
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and proliferation and enhanced invasiveness(100). Santhekadur et al in 2012, unraveled a 
linear pathway in which SND1-induced activation of NF-κB resulted in induction of miR-
221 and subsequent induction of angiogenic factors Angiogenin and CXCL16. Because 
SND1 regulates NF-κB and miR-221, two important determinants of HCC controlling the 
aggressive phenotype, they suggested SND1 inhibition might be an effective strategy to 
counteract this fatal malady(92). Recently, Fornari et.al was identified, MDM2, a known 
p53 (TP53) modulator, as a direct target of miR-221 and a feed-forward loop was 
described that sustains miR-221 aberrant expression. Interestingly, miR-221 can activate 
the p53/MDM2 axis by inhibiting MDM2 and, in turn, p53 activation contributes to miR-
221 enhanced expression. Moreover, by modulating p53 axis, miR-221 impacts cell cycle 
progression and apoptotic response to Doxorubicin in HCC-derived cell lines. Finally, 
CpG island methylation status was assessed as a causative event associated with miR-221 
up-regulation in HCC cells and primary tumor specimens. In HCC-derived cell lines, 
pharmacologically-induced DNA hypomethylation potentiated a significant increase in 
miR-221 expression. These data were confirmed in clinical specimens of HCC in which 
elevated miR-221 expression was associated with the simultaneous presence of wild-type 
p53 and DNA hypomethylation. In all, they  revealed a novel miR-221 sustained 
regulatory loop that determines a p53-context-specific response to Doxorubicin treatment 
in HCC(154).  
Yuan et al in 2013 hypothesized that modulation of miR-221 targets in primary 
hepatocytes enhances proliferation, providing novel clues for enhanced liver regeneration. 
They demonstrated that miR-221 enhances proliferation of in vitro cultivated primary 
hepatocytes. Furthermore they showed that adeno-associated virus-mediated over-
expression of miR-221 in the mouse liver also accelerates hepatocyte proliferation in vivo. 
They identified Aryl hydrocarbon nuclear translocator (Arnt) messenger RNA (mRNA) as 
a novel target of miR-221, which contributes to the pro-proliferative activity of miR-221 
and concluded that Pharmacological intervention targeting miR-221 may thus be 
therapeutically beneficial in liver failure by preventing apoptosis and by inducing liver 
regeneration(155). In 2011 Sharma et al. showed that ectopic expression of miR-221 
protects primary hepatocytes and hepatoma cells from apoptosis. Importantly, in vivo over-
expression of miR-221 by adeno-associated virus serotype 8 (AAV8) delays FAS-induced 
fulminant liver failure in mice. Additionally they demonstrate that miR-221 regulates 
hepatic expression of p53 up-regulated modulator of apoptosis (Puma), a well-known 
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proapoptotic member of the Bcl2 protein family. They suggested that miR-221 may serve 
as a potential therapeutic target for the treatment of hepatitis and liver failure(156). 
Expression patterns of miRNAs and their role in the pathogenesis of hepatocellular 
carcinoma (HCC) was assessed by Pineau et. al. using 104 HCC, 90 adjacent cirrhotic 
livers, 21 normal livers as well as in 35 HCC cell lines. miR-221/222, the most up-
regulated miRNAs in tumor samples, are shown to target the CDK inhibitor p27 and to 
enhance cell growth in vitro. In addition, they showed, using a mouse model of liver 
cancer, that miR-221 over-expression stimulates growth of tumorigenic murine hepatic 
progenitor cells. Taken together, these data revealed an important contribution for miR-221 
in hepatocarcinogenesis and suggested a promising approach to liver cancer 
treatment(103). Park et al in 2011 conducted a preclinical investigation of the therapeutic 
efficacy of oligonucleotides directed against the oncogenic microRNA miR-221, which has 
been implicated in HCC. Chol-anti-miR-221 significantly reduced miR-221 levels in liver 
within a week of intravenous administration and in situ hybridization studies confirmed 
accumulation of the oligonucleotide in tumor cells in vivo. In the same period, chol-anti-
miR-221 reduced tumor cell proliferation and increased markers of apoptosis and cell-
cycle arrest, elevating the tumor doubling time and increasing mouse survival. They 
offered a preclinical proof of efficacy for chol-anti-miR-221 in a valid orthotopic mouse 
model of HCC, suggesting that this targeted agent could benefit treatment for patients with 
advanced HCC(79). The relationship between miR-221 over-expression and 
clinicopathological parameters in HCC formalin-fixed paraffin-embedded (FFPE) tissues 
was showed by Rong et.al. in 2013. They showed the relative expression of miR-221 in 
clinical TNM stages III and IV was significantly higher than that in the stages I and II. The 
miR-221 level was also up-regulated in the metastatic group compared to the non 
metastatic group. Furthermore, miR-221 over-expression was related to the status of tumor 
capsular infiltration in HCC clinical samples. Functionally, cell growth was inhibited, cell 
cycle was arrested in G1/S-phase and apoptosis was increased by miR-221 inhibitor in 
vitro. Likewise, miR-221 mimic accelerated the cell growth. They concluded that 
expression of miR-221 in FFPE tissues could provide predictive significance for prognosis 
of HCC patients. Moreover, miR-221 inhibitor could be useful to suppress proliferation 
and induce apoptosis in HCC cells. Thus miR-221 might be a critical targeted therapy 
strategy for HCC(157). High expression of miRNA-221 also can be used to predict local 
recurrence of HCC, and fold changes in miRNA-221 less than 1 can be used as a predictive 
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marker of metastasis after curative surgical resection in patients with HCC(158). Youn et 
al in 2011 proposed the potential of microRNA-221 dysregulation for predicting local 
recurrence and distant metastasis after curative surgery(158). 
To investigate whether the serum miR-221 expression correlates with clinicopathologic 
features and the prognosis of hepatocellular carcinoma (HCC)patients, Serum miRNA 
expression was investigated in 46 HCC patients and 20 healthy normal controls by using 
real-time PCR technique, and then correlations between miR-221 expression and the 
clinicopathological features and prognosis of HCC patients were evaluated by Li et al in 
2011. Results showed that high level of miR-221 expression was correlated with tumor 
size (P < 0.001), cirrhosis (P = 0.003) and tumor stage (P = 0.016). In addition, Kaplan–
Meier survival analysis showed that the overall survival rate of the high miR-221 
expression group (27.6%) was significantly lower than that of the low miR-221 expression 
group (62.3%, P < 0.05). Therefore serum miR-221, can provide a potential predictor for 
prognosis of HCC patients(159). 
1.4.4. microRNA-199 and HCC 
 
Among down-regulated miRNAs, the miR-199–miR-214 cluster is of particular interest 
because it is down-regulated in the majority of hepatocellular carcinomas (HCCs) (138, 
142, 145, 160). Both Kim and Migliore identified the c-Met proto-oncogene as a target of 
the miR-199a-3p(117, 161). Particularly, they demonstrated that miR-199a-3p inhibits not 
only proliferation, but also motility and invasive capabilities of tumor cells by 
downregulating both c-Met and its downstream effector ERK2 (117). Its tumor suppressor 
function has been more strengthened because the mammalian target of rapamycin (mTOR) 
was also shown to be a target of miR-199a-3p. The inhibitory role of this microRNA in 
mTOR pathway is able to modulate cell proliferation and the invasion capability(128). The 
other strand of the same precursor miR-199a, miR-199a-5p, was demonstrated by Shen Q 
et al, to target Discoidin Domain Receptor (DDR1) gene. DDR1 is a tyrosine kinase 
receptor that is over-expressed in several human cancers(162, 163). More than 50% of 
HCC tissues and cells showed significant down-regulation of miR-199a-5p, with increased 
expression of the pro-invasion molecule DDR1. A down-regulation of miR-199a-5p 
expression, reported in HCC patients, could promote tumor progression enhanced by 
DDR1 up-regulation(127) . Interestingly, miR-199a was also involved in inflammatory 
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reactions associated with alcoholic diseases, most of which are mediated by molecules of 
the hypoxia-associated pathway(164). In this context, the expression of HIF-1α mRNA 
(hypoxia-inducible factor-1 α) and its coregulated gene, ET-1, were shown to be targets of 
miR-199(165), suggesting a new potential approach in the control of ethanol induced 
inflammation. Studies on steatohepatitis indicated that mice fed with different diets to 
induce alcoholic or non-alcoholic fatty livers showed different miR-199a-3p profiles, with 
down-regulation in the former and up-regulation in the latter (166). 
In liver samples from patients with hepatitis C virus (HCV) infection, and mouse fibrosis 
livers induced by CCL4, both miR-199a-3p and -5p were up-regulated in a fibrosis 
progression-dependent manner(167). Detailed research showed that activated FXR 
protected liver cells from injury through the induction of LKB1. However, in fibrotic 
livers, lowered expression of FXR resulted in elevated miR-199a-3p, which in turn 
suppressed the expression of its direct target LKB1(121). miR-199 was shown to have an 
anti-viral effect. MiR-199-a was also identified as having a target sequence in the internal 
ribosomal entry site (IRES) of HCV viral genome, highly conserved in all HCV 
genotypes(168).  Murakami et al. have shown that the inhibition of miR-199 activity by a 
specific AMO causes an increase of HCV replication, suggesting that this miRNA could 
negatively regulate the viral replication and proliferation(169). The viral replication effects 
of miR-199a-3p were also demonstrated for hepatitis B virus (HBV). Besides interaction 
with viral elements, its antiviral effects were shown to be caused by the down-regulation of 
several pathways including ERK/MAPK signaling, prostaglandin synthesis, oxidative 
stress signaling and PI3K/AKT signaling. miR-199a-3p may also play a role in regulation 
of HBV replication by targeting the HBV S protein coding region, the pre-S coding region 
and the ORF of HBV polymerase (170).  
In summary, miR-199a is involved in various processes that become derailed in liver 
cancer in consequence of its stable down-modulation in cancer cells. In addition and 
notably, it also is involved in modulating the effects of HCC risk factors, such as the 
replication of hepatitis viruses or the effect of alcohol consumption. 
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1.5. Strategies for the Development of Therapeutics miRNAs 
 
Since primary hepatic malignancies are typically characterized by frequent recurrence and 
poor response to therapy, there is a need for the discovery of novel bimolecular target in 
order to achieve efficient response to  therapy(1).  
In consideration of the advent of onco- and tumor suppressor-miRs, much interest has been 
focused on taking microRNAs from the bench to the bedside. The advantages of miR-
based therapies are their smaller size and their ability to regulate a large number of cellular 
targets.  
The application of miRNAs in cancer therapeutics normally involves one of the two 
strategies: (1) miRNA replacement by re-introducing miRNAs with tumor suppressor 
functions to restore their function 2) Inhibition of tumor-inducing miRNAs (also termed as 
oncomiRs) using antimiRNA oligonucleotides (AMOs), small molecule inhibitors, miRNA 
masking and miRNA sponges(171). Reasonable approaches for therapy would include 
achieving “gain” or “loss” of miRNA functions in the cancer cells depicted in Figure 1.7. 
In all, studies that assessed these approaches suggested that silencing or restoration of 
miRNA function can serve as a promising therapeutic strategy for cancer treatment. 
Furthermore, As miRNAs are associated with chemo- and radio-sensitization of cancer 
cells (172), a combination approach can also be developed for improved therapeutic 
outcome(84).  
 
 
 
 
 
 
 
 
 
 
 
Figure 1.7. miRNA-based therapeutic strategies against cancer. (84) 
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 miRNA mimic 
miRNA mimics are used to restore a loss of function. This approach, also known as 
‘miRNA replacement therapy’, aims to re-introduce miRNAs into diseased cells that are 
normally expressed in healthy cells(171). In many cases, the re-introduction of these 
miRNAs leads to a re-activation of pathways that are required for normal cellular welfare 
and block those that drive the disease. Proof-of-concept for miRNA replacement therapy 
has been demonstrated by mimics of tumor suppressor miRNAs that stimulate 
antioncogenic pathways, apoptosis and ultimately lead to an eradication of tumor cells(34). 
Considering that most targeted cancer therapeutics developed to date tackle a gain-of-
function, much of the excitement around miRNA replacement therapy stems from the fact 
that it provides a new opportunity to exploit tumor suppressors. miRNA mimics can be 
delivered systemically using technologies that are also used for therapeutic siRNAs. 
Therefore, the application of miRNA mimics will face less of a delivery hurdle compared 
with protein-encoding plasmid DNA previously used in gene therapy. Besides, miRNA 
mimics are expected to be highly specific and well tolerated in normal tissues. This 
supposition is based on the fact that miRNA mimics carry the same sequence as the 
naturally occurring equivalent and are expected to target the same set of genes. Since most 
normal cells already express the miRNA in question, administration of miRNA mimics to 
normal tissue is unlikely to induce adverse events as the cellular pathways affected by the 
mimic are already activated or inactivated by the endogenous miRNA(171). 
 
 Anti-microRNA oligonucleotides (AMOs) 
Anti-microRNA oligonucleotides (AMOs) have been generated to directly compete with 
endogenous microRNAs(173). AMOs can block the interactions between miRNA and its 
target mRNAs through competitive inhibition of base-pairing(174). AMOs against miR-21 
were shown to inhibit the growth of MCF-7 cells in vivo (87). Other study has shown that 
intravenous administration of AMOs against miR-16, miR-122, miR-192 and miR-194 in 
animals offer efficient and sustained silencing of corresponding miRNAs(175). In the 
mouse model, inhibition of miR-221 with Chol-anti-miR-221 (a cholesterol-modified 
isoform of anti-221) resulted in reduction of tumor cell proliferation and increased levels 
of markers of apoptosis and cell- cycle arrest and, as a consequence, increased 
survival(79). Lab of Negrini has recently showed the effects of a modified AMO against 
miR-221 in reducing the number and size of HCC tumors in a miR-221 transgenic mouse 
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model(176). From these studies it is apparent that antimiR-221 could be exploited as a 
potential therapeutic target in HCC-related malignancies. However, the ability of AMOs to 
specifically inactivate endogenous targets has been shown to be quite inefficient. Thus, 
several modifications of AMOs have been generated to improve their effectiveness and 
stability such as the addition of 2’-Omethyl and 2’-O-methoxyethyl groups to the 5’ end of 
the molecule(177). Studies have shown that targeting of miR-21, a microRNA that is over-
expressed in many cancer types, by such methods effectively reduced tumor size in a 
xenograft mouse model based on MCF-7 cells(178). 
 AMOs conjugated to cholesterol (antagomirs) have been also been generated and have 
been described to efficiently inhibit microRNA activity in vivo(179). In addition, locked 
nucleic-acid antisense oligonucleotides (LNAs) have been designed to increase stability 
and have been shown to be highly aqueous and exhibit low toxicity in vivo(179). Antisense 
oligonucleotides targeted to miRNA was also effective primates(180, 181). 
 Small molecules inhibitors 
The down-regulation of miRNAs can also be achieved by targeting their biogenesis. In a 
recent study, several small organic molecules were screened for their potential to block 
miR-21 function and azobenzene was identified as an efficient inhibitor of miR-21 
expression(182). 
 miRNA masking 
miRNA masking are relatively new strategies employed to down-regulate miRNAs. miR-
masks are like AMOs, however, they do not directly interact with its target miRNA but 
instead bind to the pairing site of miRNAs in the 3' UTR of the target mRNA by fully 
complementary mechanism. In a rat model, miR-masks complementary to HCN2 and 
HCN4 genes masked the actions of their respective targeting miRNAs, miR-1 and miR-
133(183). In another study, protection of squint or lefty mRNAs from miR-430 was also 
reported(184). 
 MicroRNA “Sponges”  
A novel technique for reducing the interaction between microRNAs and their targets is the 
use of microRNA sponges. MicroRNA sponges are single-stranded transcripts with 
repeated miRNA antisense sequences that can sequester miRNAs from endogenous 
targets(185). Repetitive antisense miRNA binding  site  in the microRNA sponges 
structure, assume to saturate the cellular  pool of microRNA(173, 185, 186). Lewis et al. at 
2003 have shown that when the sponge is expressed at high levels, it specifically inhibits 
the activity of a family of miRNAs sharing a common seed(187).  
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Sponges offer advantages over chemically modified antisense oligonucleotide inhibitors 
for many research applications. First, these antisense inhibitors appear to be specific for 
one miRNA as they depend upon extensive sequence complementarily beyond the seed 
region. Thus, to neutralize a family of miRNAs may require the delivery of a mixture of 
perfectly complementary oligonucleotides. In addition, many cells both in vitro and in vivo 
are resistant to the uptake of oligonucleotides. By contrast, for difficult-to-transfect cell 
lines or cells in vivo, the sponge transgene can be delivered by a viral vector. Inclusion of 
an open reading frame for a selectable marker or reporter gene in the vector allows for 
selection or screening(177). This approach has been successfully used recently to knockdown 
miR-223 using a lentiviral vectors(159). 
 
1.5.1. Viral Delivery of miRNAs in Liver Disease  
 
 
The primary challenge for gene therapy is to develop a method that can deliver a 
therapeutic miRNA to target cells where proper gene expression can be achieved. An ideal 
delivery method should: (1) allow efficient entry of miRNA and its carrier into the target 
cell; (2) protect the RNA against degradation by nucleases in intercellular matrices; and (3) 
be nontoxic. To function effectively in vivo, however, miRNA modulators must cross the 
membranes of tumor cells first and then bind their targets stably in the cytoplasm. In 
general, viruses are able to mediate gene transfer with high efficiencies, as they can infect 
every cell in a tumor tissue and may induce long-term expression of miRNAs in the 
infected cell. They can also be manipulated to alter their tropism so that they can infect the 
given cell type by binding to the cell surface receptor of choice. Therefore, viral vectors 
are the preferred choice for therapeutic studies of human diseases. However, acute immune 
responses, immunogenicity and insertion mutagenesis uncovered in gene therapy clinical 
trials have raised serious safety concerns on therapeutic application of commonly used 
viral vectors(188).  
When compared with viral methods, non viral delivery approaches are less efficient. These 
methods have encountered serious obstacles in recent years, because naked RNAs are 
highly unstable in bio-fluids and are degraded rapidly by cellular nucleases. To overcome 
these challenges, efforts are being made to stabilize the miRNA by chemical modification, 
conjugation and encapsulation; and to improve its delivery to the target tissues and tumor 
cells in vivo(5).  
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Recombinant adenoviral (Ad) and AAV vectors were commonly used in such studies, 
because they do not integrate into the host genome, but replicate as episomes in the nucleus 
and stably express miRNAs. It was shown recently that AAV vectors transduce 
hepatocytes efficiently in vivo when injected through the intra-portal or intra-hepatic artery 
of healthy and cirrhotic rat livers, suggesting that they are convenient for transgene 
expression in the liver(189). AAV vectors, on the other hand, are single stranded 
adenoviruses devoid of critical genes involved in viral infection, making them relatively 
safe to administer in gene therapy trials. However, because of the difficulties in the 
construction of AAV vectors, self-complementary AAVs (scAAVs) that contain inverted 
repeats of its genome were developed. scAAVs can fold into dsDNA without the need for 
additional DNA synthesis or base-pairing between multiple vector sequences(5). 
Successful therapeutic delivery of miR-26a-expressing AAV vector has recently been 
reported in a murine liver cancer model(34). They showed that administration of miR-26a 
using adeno-associated virus (AAV) in an animal model of hepatocellular carcinoma 
(HCC) also inhibited tumor progression without toxicity .Hsu et al. (137)demonstrated the 
AAV-mediated delivery of miR-122 precursor genes to Myc-induced HCC model 
successfully inhibited tumor growth.  
Oncolytic adenovirus(Ad)-mediated gene therapy present a new modality to treat cancer. 
These vectors attack tumors via replicating in and killing cancer cells as well as 
neighboring tumor cells. Numerous Ad vectors have been generated and tested in 
preclinical studies(190, 191), some of them reaching human clinical trials(192, 193). Ad5, 
the serotype most frequently used as the parental virus for vector construction, causes mild, 
self resolving illness in infants that results in long-term immunity to the virus .  In vivo, 
Ad5 and Ad5-derived vectors replicate in various organs of the hamster, most prominently 
in the liver(194). A Recombinant Conditionally Replicative Adenoviruses (CRAds), whose 
replication was controlled by miR-199  has been recently developed in our lab by callegari, 
et al. The rAd-199T virus was designed to replicate in  HCC cells which exhibit a strong 
down-regulation of miR-199. in vitro and in vivo properties of Ad-199T, demonstrated that 
this CRAd could replicate very poorly in cells expressing miR-199, while its replication 
could proceed regularly in cells lacking the expression of this miRNA.
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Interest in microRNAs is now more than ever and the literature is getting enriched rapidly 
with reports on novel miRNAs, their validated gene targets and the development of 
miRNA-based therapeutics. While these studies are promising, further in-depth studies on 
candidate miRNAs will allow us to ascertain their potential as therapeutic targets for HCC 
treatment.  
Aims of the present project are (I) Sequestering of miR-221 expression as an oncogene as 
well as restoration of miR-199a as a tumor suppressor gene in hepatocellular carcinoma 
through developing an effective viral delivery system for in vitro and in vivo studies and 
(II) Identifying new approaches to sensitize the HCC cells to conventional chemotherapy 
agents by means of microRNAs. These Goals achieve through three steps as follows: 
I(a): Inhibition of miR-221 using a novel sequestering technology. We test the 
potential of “miRNA Sponge” technology for sequestration of endogenous up-
regulated miR-221 in HCC cell lines. We study its inhibitory effect on known 
targets of miR-221 such as p27/kip1. This part of project provides proof of concept 
for a microRNA "sponge", as a novel microRNA sequestration technique which aid 
to identify the function of oncomiRs through evaluating the effects of the reduction 
of specific microRNAs in cellular pathways. This method often require viral vector 
delivery system, so the constructs can be expressed at high levels. For achieving 
prolonged inhibition of functional microRNA, we assess delivering of decoy target  
by engineering two different recombinant viral vectors as adeno(rAd) and adeno-
associated (rAAV) virus that can be promisingly used as a therapeutic agent in gene 
therapy studies. Our optimized sponges provide a precious tool for studying the 
function of miRNA in vitro as well as in vivo and in particular for upcoming a need 
for developing novel and unconventional therapeutic approaches. 
 
I(b): Restoration of miR-199a through AAV delivery system. We took 
advantage of AAV as an viral delivery tools to restore low level expression of miR-
199a in HCC cell lines. Pre-miR-199a coding sequence are packaged in 
recombinant adeno-associated virus to achieve prolonged expression. Interestingly, 
miR-199a are among the miRNAs that down-regulated in HCC but most highly 
expressed in normal liver. In addition and notably, it is involved in modulating the 
effects of HCC risk factors, such as the replication of hepatitis viruses or the effect of 
alcohol consumption. It means that the functional mechanism of miR-199a is 
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complicated and delicately regulated. Thereby ,the recombinant AAV created in 
this study can be used as a promising tool to study the role and underlying 
molecular mechanisms of miR-199a in HCC by successful in vitro and in vivo 
studies. These findings may also have significant translational relevance for 
development of new targeted therapies. 
 
II:  The Assessment of the potency of miR-221 and miR-199a as therapeutic 
targets alone and in combination with conventional chemotherapeutic agent 
for HCC therapy. Emergence of miRNAs as a new class of gene regulators and 
their proven role in cancer progression has opened new avenues for therapeutic 
discovery. Negrini et al(176) recently showed that delivery of antimiR-221 
oligonucleotides leads to a significant reduction of the number and size of tumor 
nodules in mouse model with inappropriate over-expression of miR-221. So we 
conceived to test miR-221 loss of function in combination with conventional 
chemotherapy to potentiates growth inhibitory function of sorafenib in HCC cells. 
Also we design to test efficiency of miR-199a expression restoration alone and in 
combination with sorafenib. miR-199a-3p was shown to be a modulator of cell 
cycle. It can sensitize the cells towards drug treatment through its target mTOR. 
Experiment using mimics miR-199a oligonucleotide proposed in HCC cell lines 
and mouse model as well.  
By this means, we can be open a promising therapeutic regimen against liver cancer 
based on microRNA regulation therapy. 
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3.1. Plasmids 
 
 
A. pGL3-Control Vector (Promega, USA. Catalog No.# E1741): 
 
Vector  features: 
  
1 ~ 41: Multiple cloning region   
48 ~ 250: Promoter                               
280 ~ 1932: Luciferase gene (luc+)                                   
281 ~ 303: GLprimer2 binding site                                 
1964 ~ 2185: SV40 late poly(A) signal  
2205~2441: Enhancer                             
2499 ~ 2518: RVprimer4 binding site                                
2756: ColE1-derived plasmid replication origin   
3518 ~ 4378: β-lactamase gene (Ampr)                             
4510 ~ 4965: f1 origin                                                        
5096 ~ 5249: upstream poly(A) signal                               
5198 ~ 5217: RVprimer3 binding site  
 
 
 
 
  
CHAPTER 3 MATERIALS AND METHODS 
 
B. pAAV(DJ)-IRES-GFP Expression vector (Cell Biolabs, USA, Catalog No.# 
VPK-418-DJ) 
 
 
Vector Features:  
1 ~ 141: Left ITR  
150 ~ 812: CMV Promoter  
820 ~ 1312: human β-globin intron  
1319 ~ 1373: MCS  
1418 ~ 1996: IRES  
1997 ~ 2716: GFP  
2728 ~ 3206: PolyA  
3246 ~ 3386: Right ITR  
4303 ~ 5163: Ampicillin Resistance  
• MCS Enzyme Sites: 5’- ClaI, BamHI, EcoRV, XhoI, EcoRI, XhoI -3’  
• MCS Sequence:  
CATCGATTGAATTGGATCCGATATCTAGACAGAAGCTTGACCTCGAGCACGAA
TTCCTGCAGGCCTCGAGG 
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C. pAAV-DJ Vector (Cell Biolabs, USA. Catalog No. # VPK-418-DJ) 
 
 
 
Vector Features:  
6 ~ 1871: AAV-2 Rep  
1888 ~ 4101: AAV-DJ Cap  
5606 ~ 6466: Ampicllin Resistance 
 
 
 
 
D. pHelper Vector (Cell Biolabs, USA. Catalog No. # VPK-418-DJ) 
 
 
Vector Features:  
1 ~ 5336: Adeno E2A  
5337 ~ 8537: Adeno E4  
8535~ 9280: Adeno VA  
10182 ~ 11042: Ampicillin Resistance  
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E.  pAAV-GFP Vector (Cell Biolabs , Catalog No. # VPK-418-DJ) 
 
Vector Features:  
1 ~ 141: Left ITR  
150 ~ 812: CMV Promoter  
820 ~ 1312: human β-globin intron  
1335 ~ 2075: GFP  
2134 ~ 2612: PolyA  
2652 ~ 2792: Right ITR  
3709 ~ 4566: Ampicllin Resistance  
 
 
F. pIRESneo2 miR-199a 
Gifted from Lab of Prof. Negrini  
Vector Features:  
 
 
 
  
This vector express  miR-199a under 
control of CMV promoter. Also it 
consist of Ampicillin and Neomicin 
resistance genes. In this study, 
pIRESneo2 miR-199a was used as a 
source of miR-199a sequence. 
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3.2. Primers 
 
The Primers and probes that used in this study are listed in Table 3.1. 
Table 0.1.List of primers and probes 
Name Sequence Application 
pAAV-antimiR221-1339F 5'TATCTAGTCTAGACCCGAAACCCA3'  
Cloning steps of   pAAV-miR-221sponge-IRES-GFP pAAV-antimiR221_1941R 5'TACGCTTGAGGAGAGCCATT3' 
miR-199NheI FWD 5'GCTAGCGACCCCCAAAGAGTCAGACA3'  
Cloning steps of   pAAV-miR-199-IRES-GFP 
miR-199NheI REV 5'GCTAGCCCACCCTCTTAGATGCCTCA3' 
luc_296_F 5'GTTCGGTTGGCAGAAGCTAT3' Cloning steps of pAAV-IRES-luc constructs 
luc_764_R 5'ATAGGATCTCTGGCATGCGA3' 
Hβ-actinDNA2810Fwd 5′-AGCTGTCACATCCAGGGTCC-3′ Quantitative real time PCR for normalizing 
Hβ-actinDNA2960Rev 5′-TCATACTCCTGCTTGCTGATCC-3′ 
wtAd5Fwd 5′-CGCATACGAGCAGACGGT GAAC-3′ Quantitative real time PCR 
wtAd5Rev 5′-GCACTATAAGGAACAGCTGCGCC-3′ 
EGFP_ 1318_Fwd 5'ACGTAAACGGCCACAAGTTC3'  
Real time PCR EGFP_1584_ Rev 5'AAGTCGTGCTGCTTCATGTG3' 
hsa-miR-221 
(Target Sequence) 
 
5'AGCUACAUUGUCUGCUGGGUUUC3' 
TaqMan® MicroRNA Assays. miRBase Accession 
Number MIMAT0000278, Primer Cat≠RT000524 
Probe Cat ≠TM000524 
hsa-miR-199a-3p 
(Target Sequence) 
 
5'ACAGUAGUCUGCACAUUGGUUA3' 
TaqMan® MicroRNA Assays. miRBase Accession 
Number MIMAT0000232 Primer  Cat≠RT2304 
Probe Cat ≠TM002304 
RNU6B 
(Target Sequence) 
5'CGCAAGGAUGACACGCAAAUUCGUGAA
GCGUUCCAUAUUUUU3' 
TaqMan® MicroRNA Assays Primer Cat≠RT001093 
Prob Cat≠TM001093 
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3.3. DNA and Protein Marker/Ladder  
 
 DNA Ladder(Gene Ruler):  
I. 123bp DNA Ladder(Invitrogen corporation, USA, Catalog No.# 15613-011) with 
size range between 123 to 3075bp.  
II. 1 kb DNA Ladder(New England Biolabs, USA, Catalog No.# N3232S)with 
effective size range between 500bp to 10,002bp.  
III. Lambda HindIII dsDNA Markers (Ambion, Inc. Applied Biosystems, USA, 
Catalog No.≠AM7720). 0.5 mg/mL.  
 Protein Marker 
SeeBlue® Plus2 Pre-Stained (Novex®)Life technology,USA. Catalog No.≠LC5925 
123 DNA Ladder 1Kb DNA Ladder Lambda DNA/HindIII DNA Ladder Protein Marker 
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3.4. Vector Construction 
 
3.4.1. Competent cell perparation 
 
 we used E.coli DH10β (Invitrogen, Carlsbad, CA, USA) in the form of competent cell in 
the cloning and sub-cloning steps. This strain is both endonuclease deficient (endA1) and 
recombination deficient (recA). recA1 mutation,  improves clone stability by inhibiting the 
homologous recombination system; endA1 mutation, which inactivates the encoded 
periplasmic DNA-speciﬁc endonuclease, thereby enhancing DNA stability during 
transformation and greatly improves the quality of plasmid miniprep. the Genotype of host 
strain has indicated in Table below. 
 
Host strain Genotype 
DH10B™ 
 
F– mcrA Δ(mrr-hsdRMS-mcrBC) Φ80lacZΔM15 ΔlacX74 recA1endA1 araD139 
Δ(ara leu) 7697 galU galK rpsL nupG λ– 
 
competent cells were prepared according to chemically protocol of B.calabretta,s lab, from 
Carmen Martin Seisdedos , a modification of C. T. Chung and R. H. Miller(195). The 
efficiency of competent cells was calculated after transformation of 100μl bacteria with 1 
ng of pBluescript SKII at 3*10
7
 CFU/ug. 
 
3.4.2. Glycerol Stocks Preparation 
 
Every plasmid construct, whether it was created or purchased, preserved as a glycerol 
stock. 
A. Reagent and solutions: 
 Appropriate LB media, liquid & solid.  
 80% Glycerol (80ml autoclaved glycerol was mixed with 20ml autoclaved ddH
2
O). 
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B. Procedure: 
I. To create a glycerol stock: 
1. Picked a single colony of the clone off of a plate and grew an overnight in the 
appropriate selectable liquid medium (e.g., LB with desired antibiotic).  
2. Made a label (clone ID # and date) for the construct. Placed this label onto a sterile 
screw cap of cryo-vial and put them on ice 
3. Added 0.5ml of the o/n culture to 0.5ml of 80% sterile glycerol in the sterile screw 
cap microcentrifuge tube (on ice) and vortexed. 
4. Froze the glycerol stock at –80
o
C.  
5. Entered any and all pertinent information (host strain, vector, cloning site(s), 
selection criteria, date prepared, origin/source and/or reference, and any other 
important information) regarding this accession into the lab stock collection book. 
Also include a map or sequence if possible.  
II. To streak out from a glycerol stock:  
1. Determined the location of the construct 
2. Took the tube and place it onto dry-iced box  
3. Scraped off a portion from the top of the frozen glycerol stock using a plastic 
inoculating loop and stroke it onto your plate. 
 
3.4.3. Restriction Enzyme Digestion 
 
 
A. Material and reagents: 
 
• DNA sample in water or TE buffer 
• 10x digestion buffer 
• Restriction enzyme 
 
B. Procedure: 
 
1. Pipetted the following material into a microfuge tube: 
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Material Final concentration 
Vector  0.1 to 4µg 
 RE Buffer  (10X) 1X 
RE enzyme 1-5u/μg DNA 
ddH2O Up to 30µl 
 
2. Incubated for 2 hours at 37◦C. 
3. 2 to 5 μl of the digested sample along with the un-cut DNA and a DNA marker 
were run on agarose gel and checked for the exact size of resulted fragments. 
Tips: 
• For checking DNA, 0.1 μg DNA used 
• For cloning, 4 μg DNA used. 
 
3.4.4. Ligation 
 
Ligation was done with 50ng of cut and purified vector in combination with 3-fold molar 
excess of insert in the presence of 1μl T4 ligase (Fermentase,USA) and 1μL of 10X T4 
Ligase buffer. Total volume was adjusted at 10μl with ddH2O. Ligation control was 
included with substituting the amount of insert with water. It allows evaluating the 
relegation efficiency. The ligation reactions were incubated at 15
o
C in a thermocycler for 
overnight. 
 
3.4.5. Transformation 
 
A. Reagents and Solutions: 
 
1. 5x KCM                KCl                0.5M 
                              CaCl2             0.15M 
                              MgCl2            0.25M 
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For Preparation of 10 ml 5x KCM,5 ml KCl (1 M)+ 1.5 ml CaCl2(1M)+ 2.5ml  MgCl2 
(1M)+ 1ml miliQ H2O were mixed , autoclaved and kept in4°C. 
 
2. SOC medium 
2.0g           Bacto-Tryptone, 0.5g Bacto-Yeast extract 
1ml           1M NaCl, 0.25ml 1M KCl  
1ml           2M Mg stock (1M MgCl2-6H2O, 1M MgSO4-7H2O), filter sterilize 
1ml           2M Glucose, filter sterilize 
Up to 100 ml ddH2O 
 
Bacto-Tryptone, Bacto-Yeast extract, NaCl and KCl were added to 97ml ddH2O, stirred to 
dissolve, Then it was autoclaved and cooled to room temp. 2M Mg stock and 2M Glucose, 
each to a final concentration 20mM were added. The complete medium was filtered 
through a 0.2um filter. The pH was adjusted to 7.0. 
B. Procedure: 
 
1. The competent cells were allowed to thaw on ice for 30 minutes.  
2. A tube containing :  
 
arrangement material volume Final 
concentration 
Second KCM(5X) 20μl 1X 
Third Ligation product or  
control vector 
5μl  
First Nuclease free water 75μl -- 
Final volume: 100μl -- 
         
          was prepared 
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3. The cells were mixed by flicking the tube gently, then 100ul  of bacteria added into 
tube(step 2) 
4. Placed on ice for 20-30min.  
5. Incubated at room temperature for 10 min. 
6. 250ul of SOC medium(preheated at 37°C) was added  and incubated for 45 min at 
37 
°
C with shaking at ~225 rpm. 
7. 100ul / and residue of the transformation mix were plated onto 100 μg/mL 
ampicillin  plates(preheated at 37
°
C) and kept in the 37
°
C incubator and grown 
overnight. 
 
3.4.6. Manipulation of DNA  
 
In cloning and sub-cloning steps of plasmid DNA, GenElute™ Plasmid Miniprep Kit 
(cat≠PLN350) (Sigma life science, St Louis, MO) was used according the manufacturer's 
instruction . Also QIAGEN Plasmid Mini  kit (cat≠12125) (Qiagen, Hilden, Germany) was 
used for amplifying the AAV Helper-Free System plasmids and preparation of high quality 
and quantity pAAV vectors for production of  recombinant AAV according the manual of 
the company. For extraction of total genomic DNA from cultured cells QIAamp® DNA 
Mini and Blood Mini kit (cat≠51304) (Qiagen, Hilden, Germany) was used according to 
the manual of product supplier. Recovery and purification of DNA fragments  from the 
agarose gel  was performed with use of Wizard® SV Gel and PCR Clean-Up System 
(cat≠A9282) (Promega, Madison, WI, USA) according to its instruction.  
 
3.4.7. Quantification of DNA and RNA 
 
The amount of DNA and RNA was measured by a Nanodrop® spectrophotometer (ND-
1000)(Thermo scientific), and the RNA quality of the samples was assessed by 
electrophoresis on agarose gel. 
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3.5. Cell Culture 
3.5.1. Cell Lines and Culture 
 
 
The hepatocellular carcinoma cell lines HepG2(P53 mutant) (ATCC HB-8065) and 
Hep3B(Null p53)(ATCC HB-8064)was obtained from the American Type Culture 
Collection (ATCC, Manassas, VA,USA). The human embryonic kidney cells, HEK293 
and HEK293FT transformed with the SV40 large T antigen and Hela cells were obtained 
from Invitrogen (Carlsbad, CA, USA). Cell lines were Cultured  in Dulbecco’s Modified 
Iscove’s Medium (IMDM) supplemented with 10% fetal bovine serum (FBS), 100U/ml 
0.1% (v/v) Gentamycin (Sigma, St Louis, MO). Cells were maintained in a humidified 
incubator at 37°C and 5% CO2 and sub-cultured every 2-3 days .Early passages (passage 
4–7) were used in each steps of this study.  
3.5.2. Counting the Cell Number 
 
At the indicated times, cells were trypsinized and the total number of cells per ml of media 
were counted using Scepter 2.0 Handheld Automated Cell Counter (Millipore Corporation, 
Billerica, MA, USA). 
 
3.5.3. Transfection  
 
Transient transfection of plasmid DNA was performed with Lipofectamine™ 2000 
(Invitrogen, Carlsbad, CA) according to the manufacturer's instructions. The Cells were 
plated at a density of 1.0×10
5
 and 1.0×10
4
 cells per well in 24 and 96 well plates, 
respectively one day prior to transfection. Just prior to transfection the media was replaced 
with transfection media without antibiotic. Transient transfections were done using 0.4µg 
of plasmid diluted in Opti-MEM I (Invitrogen, Carlsbad, CA) as recommended by the 
manufacturer. In the case of antisense oligos transfection, 100nM of antimiR-221 was 
diluted in Opti-MEM I and used according to the manufacturer’s manual. For production 
of rAAV particle, lipofectamine LTX (Invitrogen, Carlsbad, CA) was used according to 
manual of the manufacturer. All in vitro experiments were performed in triplicate. 
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3.6. Development of miR-221 Sponge/miR-199a Expressing 
Adeno and Adeno associated Virus.  
3.6.1. Construction of miR-221Sponge Oligonucleotids 
 
The Sponge oligonucleotids containing 4X miR-221 binding sites and its reverse 
complement were synthesized at IDT (Coralville, Iowa, USA). The sequences were as 
following:  
1);5′CTAGAcccGAAACCCAGCATTGGATGTAGCTcccGAAACCCAGCAATTAATG
TAGCTcccGAAACCCAGCAGAGAATGTAGCTcccGAAACCCAGCAGTTCATGTAG
CTcccT-3′  
and 
2);5′CTAGAgggAGCTACATGAACTGCTGGGTTTCGggAGCTACATTCTCTGCTGG
GTTTCgggAGCTACATTAATTGCTGGGTTTCgggAGCTACATCCAATGCTGGGTTT
CgggT-3′ 
for miR-221 target and complementary oligos, respectively. Then The two 
oligonucleotides were annealed to make double stranded DNA fragment with XbaI 
overhangs. Annealing procedure is shown below. 
 
Annealing procedure of forward and Reverse oligos for construction of miR-221sponge. 
Material volume Final concentration 
Forward oligomer(25 µM) 2  µl 1.66 µM 
Reverse oligomer(25µM) 2  µl 1.66 µM 
NaCl (0.5M) 6  µl 0.1M 
ddH2O 20 µl -- 
-- Final volume:30 µl -- 
 
Incubate 2 min at 80◦C, switch off the Thermoblock and wait temperature is cooled to 35◦C   
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Polynucleotide Kinase (PNK) (Roche Applied Science, Indianapolis,USA) was used to add 
a phosphate to the 5' end of a DNA fragment, for facilitating the cloning step.  
Phoshorylation was done as following: 
 Phosphorylation procedure of sponge fragment. 
Material volume Final concentration 
Sponge       µl 5 ng/ µl 
PNK buffer (10X) 1.5 µl 1X 
PNK enzyme 1    µl  
ATP (10mM) 1.5 µl 1mM 
  ddH2O       µl -- 
-- Final volume:15 µl -- 
Incubate  30 min at 37◦C and  10 min at 70◦C in thermoblock 
 PNK enzyme (Roche) 
 Store it  at  -20◦C until ligation 
 
We cloned annealed miR-221sponge into pGl3-Control vector (Promega, Madison, USA) 
using XbaI site immediately downstream of the firefly luciferase reporter gene. 
3.6.2. Luciferase Expression Test 
 
For luciferase expression test which demonstrate the expression of inserted luciferase 
reporter in pAAV-miR-221sponge-IRES-Luc, pAAV-miR-199-IRES-Luc and pAAV-
IRES-Luc, HEK-293 cells were plated in triplicate wells of a 24-well plate at density of 
1.0×10
5
 and transfected one day later with 0.4μg of the indicated firefly luciferase reporter 
construct and 0.04μg (1:10 ratio of reporter construct) of pRL-TK vector (Promega 
Madison WI, USA), which contains the Renilla luciferase gene (Promega). A Renilla 
luciferase vector (pRL-TK)(promega) was used to normalize experimental variability 
caused by differences in cell viability or transfection efficacy. Cells were harvested after 
24hr and washed with PBS following lysing using Passive Lysis Buffer (Promega, 
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Madison WI, USA). Firefly and renilla luciferase were measured by employing a Promega 
Dual-Luciferase® Reporter Assay System according to the supplemental manual. Data are 
represented as mean values ±SD from a representative experiment conducted with triple 
technical replicates and was shown as fold changes of average FF/renilla luminescence 
activity to non-transfected (NTC) control. 
3.6.3.  Duel Luciferase Reporter Assay 
 
HEK-293 cells were seeded at density of 1.0×10
5
 cells/well in 24-well plate. 24 h after 
seeding the cells were transfected by 200 ng of pAAV-miR-221Sponge–IRES-GFP vector 
or pAAV-IRES-GFP as a control, co-transfected along with 200 ng of firefly luciferase 
construct: pGL3-3'UTR p27(99) which encodes for a known target of miR-221; p27 
upstream of firefly luciferase gene. The pRL-TK (Promega Corporation) was also 
transfected as a normalization control at 1:10 ratio respect to firefly luciferase plasmid. The 
Renilla luciferase vector (pRL-TK)(promega) was used to normalize experimental 
variability caused by differences in cell viability or transfection efficacy. One seeded well 
was left non-transfected (NTC) as a negative control. Transfection efficiency was 
monitored by fluorescence microscopy 24h after transfection due to appearance of 
expression of green fluorescent protein. Cells were trypsinized and collected 24 h after 
transfection and luciferase activity was measured using a dual-luciferase reporter assay kit 
(Promega Corporation, San Diego, CA, USA) and recorded by illuminometer. In brief, The 
cells were washed with PBS and lysed with Passive Lysis Buffer (PBL) (promega, 
cooperation) following shaking for 15 minutes. 20μl of lysed cells was added to a 
illuminometer tube containing 100μl of Luciferase Assay Reagent II (LAR II) (promega, 
cooperation), and placed into the illuminometer without vortexing. This reagent induces 
luminescence from the firefly luciferase expressed from pGL3. After recording the 
luminescence, 100μl of Stop & Glo® Reagent (promega, cooperation) was added to the 
reaction, vortexed quickly, and the tube was returned to the illuminometer. This reagent 
quenches the luminescence of firefly luminescence and simultaneously induces the 
reaction of the Renilla luciferase (as a transfection normalizer). So Firefly luciferase 
activity was used as the primary reporter to monitor the regulation of P27/kip1(known 
target of miR-221) and Renilla luciferase acted as a control reporter for normalization. The 
relative reporter activity was obtained through normalization to the firefly-renilla luc 
activity. Data were represented as mean values from three replicate and shown as 
percentage activity by setting the firefly luciferase of control transfected sample to 100%. 
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3.6.4. Development of Recombinant Adenoviruses 
 
To produce the adenoviral vector, the adenoviral backbone from the replication-competent 
adenovirus vector Ad-199T (196) was employed. A 2,181bp fragment containing the 
SV40-Luciferase-miR-221sponge fragment from the engineered pGL3-control vector was 
sub-cloned into pAd-199T. pAd-Control vector without miR-221sponge sequence was also 
developed. The viral progeny were packaged with the use of 293FT cells and purified 
using PEG-it Virus Precipitation Solution (System Biosciences, Mountain View, CA), 
according to manufacturer’s instructions. To determine the titer of rAd-199T-miR-
221sponge and rAd-199T control viruses, 7.5×104 HepG2 cells were seeded in a 24 well 
plate; after 24 hours cells were infected with 1 microliter of either viruses. One day after 
infection, cells were harvested and total genomic DNA purified by QIAamp DNA Mini Kit 
(Qiagen, Hilden, Germany) according to manufacturer’s instructions. 50ng of genomic 
DNA was analyzed by quantitative Real Time PCR, using EVA green (Biotium.Inc, 
Hayward, CA, USA) and primers specific for wild type Ad5 sequences: wtAd5Fwd, 5′- 
CGC ATA CGA GCA GAC GGT GAA C-3′; wtAd5Rev, 5′-GCA CTA TAA GGA ACA 
GCT GCG CC-3′. PCR was performed by initial denaturation at 95°C for 15min followed 
by 40 cycles of 95°C 30 sec, 58°C 30 sec and 72°C 30 sec. A standard curve was generated 
by using serial dilutions of the plasmid pAd-Control DNA (from 10ng to 100fg) spiked in 
50ng of HepG2 non infected genomic DNA. The number of viral infectious units (I.U.) 
was determined comparing the threshold cycle (Ct) values of each sample with those of 
standard samples. Fluorescence was measured by using a Bio-Rad light Cycler Chromo 4 
thermal cycler. 
3.6.4.1. Assessment of Adenoviral Replication  
 
Genomic DNA from infected cells was extracted with the QIAamp DNA Mini Kit 
(Qiagen, Hilden, Germany) according to manufacturer’s instructions. Real Time PCR 
using EVA green (Biotium.Inc., Hayward, CA, USA) and primers wtAd5Fwd and 
wtAd5Rev specific for wild type Ad5 were utilized to assess viral replication in DNA 
content. Fluorescence was measured by using a Biorad-Chromo4 thermal cycler real time 
PCR instrument. Human β-actin gene was used to normalize data. Primers were as follows: 
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Hβ-actinDNA2810Fwd, 5′-AGC TGT CAC ATC CAG GGT CC-3′; Hβ-
actinDNA2960Rev, 5′-TCA TAC TCC TGC TTG CTG ATC C-3′. 
 
3.6.5. Development of Recombinant Adeno-Associated Virus  
 
The AAV-DJ Helper Free Bicistronic Expression System (GFP) (Catalog Number : VPK-
418-DJ) including: pAAV-DJ-IRES-GFP expression Vector (Part No. VPK-418), pAAV-
DJ Vector (Part No. 340001) carrying the replication and capsid formation genes and  
pHelper Vector (Part No. 340202) harboring adenovirus needed genes for production of 
AAV viral particle as well as pAAV-GFP Control Vector (Part No. AAV-400) were 
purchased from Cell Biolabs, Inc.(San Diego, CA 92126 USA). The cassette of  miR-
221sponge from pGL3-Control was cloned upstream of IRES-GFP sequence into pAAV-
IRES-GFP Expression Vector using XbaI site to produce “pAAV-miR-221Sponge-IRES-
GFP” vector. In the interest of using this system in vivo, pAAV vector which 
simultaneously expressed miR-221sponge and Luc reporter gene were prepared by 
substituting the GFP cassette with Luc firefly gene in pAAV-miR-221Sponge-IRES-GFP. 
Recombinant pAAV-199-IRES-GFP was created by substitution of miR-199a expressing 
fragment by miR-221Sponge in pAAV-miR-221Sponge-IRES-GFP. The recombinant 
AAV expression and helper plasmids were prepared in sufficient quantities with high 
quality and purity using QIAGEN Plasmid Mini kit (cat≠12125) (Qiagen, Hilden, 
Germany). One day before transfection, sufficient 293FT cells plated  to achieve 70-80% 
confluence on the day of transfection. Infectious rAAV was generated by triple-
transfection of pAAV Expression Vector (pAAV-miR-221Sponge, pAAV-miR-199a or 
control vectors),  pAAV-DJ, and phelper at molar ratio of 1:1:1 into 293FT a commonly 
used AAV production cells, contains the adenoviral E1A/E1B genes.  A Total of 30μg of 
plasmid DNA was considered per each 175 cm2 cell culture flask. Transfection efficiency 
was monitored under fluorescence microscope by observation of bright green fluorescence. 
Following incubation for 3 days, the 293FT cells were harvested for virus purification. In 
brief, 0.5 M EDTA to a final of 10mM was added to the plate and incubated for 3 min at 
room temperature. Then the culture plate was gently shacked several times. Because 
viruses are present in both intact cells and the growth medium, all media including cells 
were harvested. The cell suspension was centrifuged at 1000 RPM for 5 min. rAAV crude 
lysates were prepared by resuspending the cell pellet in 2ml sterile PBS followed by four 
round of freezing-thawing by placing it alternately in a dry ice/ethanol bath and a water 
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bath of 37ºC. The lysates were centrifuged at 10,000 g for 10 min to remove cell debris of 
the host cells. rAAV was purified by using ViraBind™ AAV Purification Kits (Cell 
Biolabs, Inc.San Diego, CA 92126 USA) according to manufacturer’s protocol. Purified 
Viral stocks were aliqouted and stored at –80°C. 
3.6.5.1. Adeno-Associated Virus Titration by Real Time PCR 
 
 Genomic Titration of AAV 
Titration of Genomic particle of virus was carried out in Bio-Rad light Cycler chromo 4 by 
absolute quantitative real-time PCR approach using EVA green (Biotium Inc, Hayward, 
CA, USA). The virus crude were supplemented with 10U DNase1 and nuclease reaction 
buffer (Promega, Madison, WI, USA), and incubated for 30 min at 37 ◦C, followed by an 
inactivation step (97 ◦C, 15 min). 1μl of virus stock and 10 to1000 serial diluted was 
analyzed by quantitative Real-Time PCR, using primers specific for GFP 
sequences(EGFP_ 1318_Fwd and EGFP_1584_ Rev ,see table 3.1 for details). Final 
concentration of 0.2μM of each EGFP 1318F and EGFP 1584R were used as forward and 
reverse primes respectively. PCR was performed by initial denaturation at 95°C for 15min 
followed by 35 cycles of  95◦C for 30 s, 58◦C  for 30 s and 72◦C for 30 and melting curve 
analysis. A standard curve was generated by using serial dilutions of the pAAV-IRES-GFP 
(from 10ng to 100fg). PCR products were analyzed by agarose gel electrophoresis (2%), 
the expected product length was 187bp through electrophoresis at 80mv in TAE 0.5X 
Buffer. Genomic  particle per ml was calculated as: [a*b/c]*1000 in which a: number of 
molecule b: medium of concentration of DNA(pg) for technical triplicate and c: molecular 
weight of (pg).  
Infectious Titration of AAV  
Titration of infectious of virus was carried out in Bio-Rad light Cycler chromo 4 by 
absolute quantitative real-time PCR approach using EVA green (Biotium Inc, Hayward, 
CA, USA). For titration of the infectious particles, 7.5×10
4
 Hella cells per well were 
seeded in 24-well plates and infected with 1μl of purified viral stock. Uninfected Hella 
cells served as negative control. After 72h, cells were trypsinized, pelleted and washed 
once with PBS then resuspended in 50μl PBS. Total genomic DNA of cell pellet was 
extracted by QIAmp DNA Mini Kit (Qiagen, Hilden, Germany) according to 
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manufacturer
’
s instructions. 200ng of genomic DNA was analyzed by quantitative Real-
Time PCR, using primers specific for GFP sequences (see table 3.1). PCR was performed 
by initial denaturation at 95°C for 15min followed by 35 cycles of  95◦C for 30 s, 58◦C  for 
30 s and 72◦C for 30 and melting curve analysis. A standard curve was generated by using 
serial dilutions of the pAAV-GFP (from 10ng to 100fg) plus 200ng of Hella non infected 
genomic DNA. The number of viral infectious units (I.U.) was determined comparing the 
threshold cycle (Ct) values of each sample with those of standard samples.  
3.6.6. Viral Infection for Molecular Assay of rAAV  
 
Hep3B or HepG2 cells were seeded at 1.0×10
5
 per well in a 24-well plate. Twenty-four 
hours post-seeding, rAd-199T-miR-221sponge or corresponding control virus and rAAV-
miR-221sponge or rAAV-miR-199a or rAAV-control at appropriate MOI were diluted in 
300μl of IMEM(+10%FBS and 1%Gentamicine) and added onto the cells.  Transduction 
efficiency, was monitored using fluorescent microscope. 72hr post transduction, cells were 
harvested for RNA and protein analysis or subjected for cell viability and apoptosis assay 
.Trypsinized cells were pelleted in 0.3g for 5 min. Supernatant was removed, cell pellet 
was homogenized in TRIzol and followed for RNA extraction (see 3.23.1.1.)  or frozen at -
80◦C. For protein preparation cell pellets was washed with 500μl PBS and centrifuged one 
more time at 0.3g for 5min. The supernatant was removed and the pellet frozen at -80◦C or 
subjected freshly for protein analysis. 
 
3.7. Combination therapy of AntimiR-221/miR-199a 
Oligonucleotides and Sorafenib. 
 
3.7.1. Oligonucleotides and Therapeutic Reagent 
 
A. The anti-miRNA oligonucleotide (AMO)  
Anti-microRNA oligonucleotides was purchased from Integrated DNA Technologies 
(Leuven, Belgium) and scrambled negative control#2 was obtained from Ambion, Life 
Technologies (Grand Island, NY 14072 USA). Anti-Oligonucleotides contained the natural 
nucleotides and were chemically modified to contain a phosphorothioate (PS) linkage. The 
sequence of anti-miRNA oligonucleotide (AMO) against miR-221 was: 5’-
mG*mA*mAmAmCmCmCmAmGmCmAmGmAmCmA mAmUmGmU*mA*mG* 
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mC*mU-3’ (where ‘‘m’’ represents 2’-Omethyl RNA bases and asterisk [*] indicates the 
presence of a phosphorothioate internucleoside linkage. While unmodified 
oligodeoxynucleotides can display some antisense activity, they are subject to rapid 
degradation by nucleases and are therefore of limited utility. The simplest and most widely 
used nuclease-resistant chemistry available for antisense applications is the 
phosphorothioate (PS) modification. In phosphorothioates, a sulfur atom replaces a non-
bridging oxygen in the oligo phosphate backbone. PS oligos can show greater non-specific 
protein binding than unmodified phosphodiester (PO) oligos, which can cause toxicity or 
other artifacts when present at high concentrations. Non-specific protein binding of PS 
oligos can be minimized by making the oligonucleotide as short as possible (thereby 
reducing PS content) or using chimeric designs with 2'-O-methyl RNA. The use of 2′-O-
methyl (2'OMe) RNA in chimeric antisense designs, increases both nuclease stability and 
affinity (197) of the antisense oligo to the target mRNA [3–5]. These modifications, 
however, do not activate RNase H cleavage. 
 
B. Pre-miR™ miRNA Precursor Molecule 
Pre-miR™ miRNA Precursor Molecules are small, chemically modified double-stranded 
RNA molecules designed to mimic endogenous mature miRNAs. These ready-to-use 
miRNA mimics, although are similar to, but not identical to siRNAs. Pre-miR miRNA 
Precursor Molecules have been modified to ensure that the correct strand, representing the 
desired mature miRNA, is taken up into the RNA-induced silencing-like complex 
responsible for miRNA activity. They are not hairpin constructs, So should not be 
confused with pre-miRNAs 
Pre-miR miRNA Precursors were used in this study to assess miRNA function by up-
regulation of miRNA activity. They introduced into the cells using standard Lipofection 
methods for lipofectamine 2000. Thanks to their small size, they are easier to transfect than 
vectors, and can be delivered using conditions identical to those used for siRNAs. Positive 
and negative control Pre-miR Precursors be used to optimize transfection of Pre-miR 
miRNA Precursors. Pre-miR Precursors used in this study was as follows : 
miRBase ID  miRBase Accession # Cat. #  Assay ID: 
hsa-miR-199a-3p MIMAT0000232 AM17100 PM11779 
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C. Sorafenib(Nexavar®) 
Sorafenib[N-(3-trifluoromethyl-4-chlorophenyl)-N0-(4-(2-methylcarbamoylpyridin-4-
yl)oxyphenyl)urea] was provided by the Bayer Corporation (West Haven, CT). For in vitro 
studies, sorafenib was dissolved in Cremophor EL/95% ethanol (50:50; Sigma-Aldrich) 
and diluted in 10% FBS-containing IMDM to the desired concentrations. Drug 
concentrations were chosen in accordance with serum concentration that can be achieved 
in clinical settings. Cremophor EL/95% ethanol (50:50) was added to cultures at a 
concentration equal to that of drug-treated cells, as a solvent control. 
3.7.2. IC50 Determination of Sorafenib 
 
For determination of the IC50 of sorafenib in HepG2 and Hep3B cells, 1.0×10
4
 cells were 
seeded in a 96-well plate and treated with increasing doses of sorafenib from 0.01μM to 
10μM. After appropriate time point cells were incubated with CellTiter-Glo® Luminescent 
Cell Viability kits (Promega Corporation , 2800 Woods Hollow Road , Madison, WI 
53711-5399 USA)according to manufacturer’s instruction. Controls received Cremophor 
EL/95% ethanol (50:50) at a concentration equal to that of drug-treated cells. The IC50 
value of sorafenib, at which 50% of the cells were growth-inhibited compared with control, 
was calculated based on the changes of luminescence measured by Infinite F200 PRO 
Multimode microplate reader(TecanGroupLtd,Seestrasse1038708 Männedorf 
,Switzerland). 
3.7.3.  Combined Anticancer Effects of Sorafenib and Oligos (Anti-miR 
or pre-miR miRNA Precursor) 
 
HCC cells ,Hep3B and HepG2, were seeded in a 24-well plate (1×105  cells per well) or a 
96-well plate (1×10
4
  cells per well) and incubated at 37°C. Just prior to transfection  the  
media was replaced with transfection media without antibiotic (400μl and 50μl  in a 24-
well and 96-well plate scales respectively). The cells were then transfected with oligo 
inhibitor or pre-miR miRNA Precursor at a final concentration of 100nmol/L and  
Sorafenib at established concentration alone or in combination.  Scramble miRNA 
inhibitor, vehicle and untreated negative control  also were considered. Transfection were 
completed by using lipofectamin 2000(invitrogen) as recommended by the manufacturer. 
Transfection efficiency of Oligonucleotides was measured using a BLOCK-iT™ 
Fluorescent Oligo control for lipid transfection Catalog No. ≠460926. The 
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transfected/treated cells were analyzed for apoptosis and cell viability after 24 and/or 48 
hours or harvested and cellular or molecular analyses were done on cell pellets. For each 
experiment triple wells were conducted. 
 
3.7.4.  In vivo study 
 
All animal experimentation  were undertaken in accordance with the National Institute of 
Health Guide for the Care and Use of Laboratory Animals, with the approval of 
institutional ethical committee in Italy. The miR-221 transgenic strain (TG221), which is 
predisposed to the development of liver cancer, were used for evaluating the anti-tumor 
activity of miR-199a treatments and its combination with chemotherapeutic treatment in 
vivo. TG221 mouse strain has an increased susceptibility to the carcinogen 
diethylnitrosammine (DEN) (Sigma-Aldrich, St.Louis, MO, USA) and tumors exhibit a 
miRNA profile similar to human HCC, including the down-regulation of miR-199a.  
The mice were maintained in a vented cabinet at 25°C with 12-hour light-dark cycle and 
provided food and water ad libitum.  
To facilitate tumor development, DEN was injected intra-peritoneally (7.5 mg/kg body 
weight) at day 10 after birth.  At 5 months after birth, mice were randomly distributed into 
four groups (n=6  per group) and treated as follows: 
 Group 1: received three intraperitoneal injections of miRNA-199 mimic every 
week for three weeks, for a total of nine injections (1 mg in total);  
 Group 2: received a dose of Sorafenib (5mg/kg) x os every day for a total of 21 
days;  
 Group 3: received both miRNA-mimic and Sorafenib treatments as described 
above;  
 Group 4: was untreated and represented as the control group.  
The miRNA mimic miR-199a oligonucleotide was obtained from Axolab (Kulmbach, 
Germany). Sorafenib (Bay 43-9006) was obtained by  Selleckchem (Munich, Germany). 
The mice were sacrificed at 6 months of age and subjected to autopsy. Livers were partly 
fixed in 10% formalin for histopathological investigations and partly frozen in liquid 
nitrogen for molecular studies. Liver RNA was isolated by using Trizol reagent 
(Invitrogen), according to the manufacturers’ procedures. 
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3.8. Quantitative Molecular Assays 
 
3.8.1. miRNA Analysis 
 
 RNA isolation 
Total RNA was isolated from cultured cells in duplicate at appropriate time point post-
transfection and homogenized in 1mL of TRIzol®Reagent(Ambion®) (Invitrogen, 
Carlsbad, CA, USA). The homogenized samples were incubated for 5 minutes at room 
temperature to permit complete dissociation of the nucleoprotein complex. 0.2 mL of 
chloroform per 1mL of TRIzol was added and the tubes were shaked vigorously by hand 
for 15 seconds. After 2–3 minutes incubation at room temperature, the samples were 
centrifuged  at 12,000 × g for 15 minutes at 4°C. The aqueous phase of the samples were 
removed and placed  into new tubes. 0.5 mL of 100% isopropanol was added to the 
aqueous phase, per 1mL of TRIzol® Reagent used for homogenization. The samples were 
incubated  at room temperature for 10 minutes followed by centrifuge at 12,000 × g for 10 
minutes at 4°C. The RNA pellets were washed with 500μL of 75% ethanol. the samples 
were vortexed briefly, then centrifuged at 7500 × g for 5 minutes at 4°C. The wash was 
discarded. the RNA pellets were air dried for 5–10 minutes and resuspended  in 30μl of in 
RNase-free water. Absorbance of RNA at 260 nm and 280 nm was used to determine 
concentration. Extracted RNA were qualified on the 0.8% agarose gel. 
 miRNeasy Kit Purification 
The miRNeasy Mini Kit allows purification of miRNA with total RNA for use in a variety 
of applications, including: Quantitative, real-time RT-PCR. miRNeasy Mini Kit used 
according to manufacturer’s manual(Qiagen Catalog NO.≠217004). 
 miRNA TaqMan RT-PCR for Quantification of miRNA 
The mature miRNA was quantified by quantitative PCR (qPCR) using the TaqMan 
microRNA Assays (Applied Biosystems, Grand Island, NY, USA). To measure the amount 
of mature miRNA, a two steps TaqMan real-time PCR analysis was performed, using the 
custom primers and probes supplied in TaqMan® MicroRNA Assays kit (Applied 
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Biosystems, Grand Island, NY, USA)(see table 3.1). Reverse transcription reaction was 
done starting from 5ng of total RNA. In a reaction volume of 7.5μl, cDNA was synthesized 
using reverse transcriptase and the stem–loop primer for miR-221/miR-199a-3p (Applied 
Biosystems; cat# PN 4427975) or RNU6B (internal control; Applied Biosystems; PN 
4373382). The reverse transcriptase reaction was performed by incubating the samples at 
16°C for 30 min, 42°C for 30 min, and 85°C for 5 min. Subsequently, qPCR (10mL 
reaction) was carried out in triplicate using a 1:15 dilution of cDNA , 5μL of the TaqMan 
2✕ Universal PCR Master Mix and 0.5μl of TaqMan MicroRNA Assay (20✕). The PCR 
mixtures were incubated at 95°C for 10 min, and this was followed by 40 cycles of 95°C 
for 15 s and 60°C for 60 s in Bio-Rad light Cycler chromo 4. The reference gene was U6 
snRNA (RNU6B, Applied Biosystems, Grand Island, NY, USA).  
Using iCycler iQ5 optical system software (BioRad, Hercules, CA), threshold cycle 
(beginning of the PCR exponential phase) values were analyzed. The levels of miR-221/ 
miR-199a-3p expression were normalized after subtracting the Ct value of the U6 snRNA 
internal control from that of miR-221/ miR199a-3p Ct value for samples. The relative 
expression levels of miRNAs were calculated using the comparative ΔΔCt method. The 
fold changes in miRNAs were calculated by the equation 2
-ΔΔCt
. Down/Up regulation of 
miRNAs were established when the differences in miRs expression were statistically 
significant between antimiR/ mimics  treated and untreated control samples (P<0.05). 
 
3.8.2. Protein assay 
 
 Protein Preparation  
Total protein from mammalian cell lines were prepared using RIPA lysis buffer (150mM 
NaCl, 0.1% SDS, 0.5% sodium deoxycholate, 1% NP-40) (Sigma, St Louis, MO) with 
complete protease and phosphatase inhibitor cocktails (Sigma, St Louis, MO,USA). 
Homogenates were then centrifuged at 13000 rpm for 15 min at 4°C and supernatants 
collected. Protein concentration was measured using Bradford Reagent and the BSA 
Protein for tracing a standard curve. 
 
 Western Blotting 
A. Reagents and Solutions 
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 SDS-PAGE Running Buffer 
Tris-base 3.0 g 
Glycine 14.4 g 
20% SDS 5 ml 
Add ddH2O to 1 L 
 
 Western Blot Transfer Buffer 
Tris-base 3.0 g 
Glycine 14.4 g 
Methanol 200 ml 
Add ddH2O to 1 L 
 
 TBS Buffer(pH 7.4) 
 
Tris-base 2.420 g 
NaCl 8.78 g 
Add ddH2O to 1 L 
Adjust the pH to 7.4 
 
 TBST Buffer  
0.05 % tween 20  
Add to TBS Buffer 
 
 Western Blot Blocking Buffer 
5% milk 
Add to TBS Buffer 
Mix well and filer 
 
 Ponceau Red Staining Solution 
Ponceau S 0.5g 
Acetic acid 25 ml 
Add ddH2O to 500 ml 
 
 
B. Procedure 
 
Thirty micrograms of total protein extracted were loaded onto 4-15% Mini-
PROTEAN® TGX™ Precast Gels (Bio-Rad Laboratories,Hercules,CA94547). The 
separated proteins were transferred to PVDF membranes (BioRad) for 2h at 100mA. After 
blocking with 5% non-fat milk ,the membrane was incubated with CDKN1B/p27 primary 
antibody (BD Transduction Laboratories™, 610242, dilution 1:1500). Beta-actin (Sigma 
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Aldrich,A4700,dilution 1:1000) was used for normalization purposes at 4◦C overnight for 
overnight. The membrane was washed three times in TBST buffer, each for 10min. Then 
followed by incubation  with Anti-Mouse IgG (whole molecule)–Peroxidase antibody 
produced in rabbit (Sigma Aldrich,A9044 dilution 1:10000) to recognize the primary 
antibodies for 1hr. at room temperature. Signals were developed with Precision Plus 
Protein Dual Color Standard (BIO-RAD) and Protein bands were visualized using the 
ChemiDoc
TM
MP Imaging System and quantified using Image lab 4.0 software (Bio-Rad 
Laboratories,Hercules,CA94547). 
 
3.9. Quantitative Cell Analysis 
 
3.9.1. CellTiter-Glo® Luminescent Cell Viability Assay  
 
The CellTiter-Glo® Luminescent Cell Viability Assay is a homogeneous method to 
determine the number of viable cells in culture based on quantitation of the ATP present, 
which signals the presence of metabolically active cells. Hep3 and HepG2 Cells were 
plated at 10,000 per well in 96-white-walled microtiter plates and incubated overnight at 
37◦C in a humidified incubator containing 5% CO2. On the following day, the cultured 
cells were expose to drug (sorafenib)  for an additional 24 or 48 hours. For each treatment 
triplicate wells were considered. Also we considered wells without cells as a blank control 
and untreated and drug solvent treated ones as negative controls. Cell viability was 
determined by adding 100μl of the CellTiter-Glo luminescent cell viability kit (catalog# 
G7571) from Promega Corporation (Madison, WI, USA) directly to cells cultured in 
serum-supplemented medium. The contents were mixed for 2 minutes on an orbital shaker 
to induce cell lysis .The plate was incubated for 90min at room temperature in a dark room 
to stabilize luminescent signal. Luminescence was recorded in Infinite F200 PRO 
multimode microplate reader(Tecan Group Ltd, Seestrasse 1038708 Männedorf 
,Switzerland). Calculation of results was done by subtracting the average of luminescence 
value of the culture medium background from all  Luminescence value of experimental 
wells. Data were confirmed in at least two independent experiments. 
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3.9.2. CellTiter-Blue® Cell Viability Assay 
 
The CellTiter-Blue® Cell Viability Assay provides a homogeneous, fluorescent method for 
monitoring cell viability. The assay is based on the ability of living cells to convert a redox 
dye (resazurin) into a fluorescent end product (resorufin). Resazurin is dark blue in color 
and has little intrinsic ﬂuorescence until it is reduced to resoruﬁn, which is pink and highly 
ﬂuorescent (579Ex/584Em). Unviable cells rapidly lose metabolic capacity and thus do not 
generate a fluorescent signal. The visible light absorbance properties of CellTiter-Blue® 
Reagent undergo a “blue shift” upon reduction of  resazurin to resoruﬁn. The absorbance 
maximum of resazurin is 605nm and that of resoruﬁn is 573nm. Either ﬂuorescence or 
absorbance may be used to record results; however, we provided  ﬂuorescence data 
because it is more sensitive and involves fewer data calculations. In addition, because 
CellTiter-Blue® Reagent is relatively non-destructive to cells during short-term exposure, 
it allows the performance of more than one aasay on the same sample and can be 
multiplexed with other assay methods such as Caspase-Glo® 3/7 Assay Systems.  
10000 Hep3 and HepG2 cells were seeded into 96- well opaque-walled tissue culture 
plates compatible with our fluorometer. After growing them in the CO2 incubator at 37°C 
for one day ,  the media was changed with media lack of antibiotic and cells were treated 
with 100nM of  antimiR-221, 1 , 5, 7 or 10μM sorafenib or both compounds for 
established time point. Treatment was done using and/or sorafenib in alone or in 
combination. Triplicate wells were considered for each treatment. Controls that included 
were : 
*Blank Control: Triplicate wells without cells were set up to serve as the negative control 
to determine background fluorescence that may be present. 
*NTC Control: Triplicate wells with untreated cells were set up to serve as a vehicle 
control.  
*CTL Control: Triplicate wells with the same solvent and the vehicle (refers here to 
transfection reagent) of compound were used to deliver the test compounds to the vehicle 
control wells.  
*Scramble control: Triplicate wells with scramble oligos (negative control#2 , Life 
technology)  to test for possible interference with the miRNA oligos sequences. 
Before starting the assay the CellTiter-Blue® Reagent was thawed at a 37°C water bath. 
The homogeneous assay procedure was performed by addition of 25μl of CellTiter-Blue® 
Reagent(Catalog#G8081)(Promega Corporation ,Madison, WI , USA), directly to cells 
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cultured in serum- supplemented medium and the cells were incubated for 1 hours at 37◦C 
prior to recording fluorescence. During incubation, the plate was protected from light and 
covered to prevent evaporation. Data are recorded using 560Ex/590Em fluorescence filter in 
the infinite F200 PRO multimode microplate reader (Tecan Group Ltd, Seestrasse 1038708 
Männedorf ,Switzerland). The fluorescence values were directly proportional to the 
number of living cells in the culture. Before calculation of results the average of 
fluorescence value of the culture medium background was subtracted from all  
fluorescence value of experimental wells. Finally the cell washed with media to adapt the 
cells for Caspase-Glo® 3/7 Assay. Viable cells was tittered as fluorescence of treated 
sample / mock control×100.  Data were confirmed in at least two independent experiments. 
 
3.9.3. Caspase-Glo® 3/7 Apoptosis Assay 
  
The Caspase-Glo® 3/7 Assay is a luminescent assay that measures caspase-3 and -7 
activities in purified enzyme preparations or cultures of adherent or suspension cells. The 
assay provides a proluminescent caspase-3/7 substrate, which contains the tetrapeptide 
sequence DEVD. This substrate is cleaved to release aminoluciferin, a substrate of 
luciferase used in the production of light. The Caspase-Glo® 3/7 Reagent is optimized for 
caspase activity, luciferase activity and cell lysis. Addition of the single Caspase-Glo® 3/7 
Reagent in an "add-mix-measure" format results in cell lysis, followed by caspase cleavage 
of the substrate and generation of a “glow-type” luminescent signal. For preparation of the 
reagent the Caspase-Glo® 3/7 Buffer and lyophilized Caspase-Glo® 3/7 Substrate were 
equilibrated to room temperature before use. Then the contents of the Caspase-Glo® 3/7 
Buffer bottle was transferred into the amber bottle containing Caspase-Glo® 3/7 Substrate. 
The contents was mixed by swirling or inverting, until the substrate is thoroughly dissolved 
to form the Caspase-Glo® 3/7 Reagent.  
Caspase-3/7 activity was measured immediately after the detection of CellTiter-Blue® Cell 
Viability Assay (described above) on the same wells, by adding 100µl of the homogeneous 
Caspase-Glo® 3/7 assay Reagent (catalog#G8091)(Promega Corporation ,Madison, WI , 
USA) at the established time after transfection and/or sorafenib treatments, to each well of 
a 96-well plate containing 100µl of blank, negative control cells or treated cells in culture 
medium. Because of the sensitivity of this assay, we Covered the plate with a plate lid. 
contents of wells gently was mixed using a plate shaker at 300–500rpm for  30 seconds, 
depending upon the cell culture system. The optimal incubation period was determined 
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empirically between 60, 90 and 120min. the luminescence of each sample was measure in 
a plate-reading illuminometer (infinite F200 PRO) (Tecan Group Ltd, Seestrasse 1038708 
Männedorf ,Switzerland), as directed by the illuminometer manufacturer. We Subtracted 
the value for the blank reaction which show the background luminescence from 
experimental values. Negative control reactions were important for determining the basal 
caspase activity of the cell culture system and vehicles (refers to solvent of drug and 
transfection solution). Caspase-3/7 activity is expressed as luminescence of treated sample 
/ mock control×100. Data were confirmed in at least two independent experiments. 
 
3.9.4.  Annexin V Apoptosis & Dead Cell Assay  
 
Apoptosis, or programmed cell death, is an important regulator of cell growth and 
proliferation. Induction of apoptosis is characterized by a progressive series of cellular 
biochemical and morphological changes. One of the hallmarks of apoptosis is the 
translocation of phosphotidylserine from the inner to the outer leaflet of the plasma 
membrane and exposure to the outer surface of the cell. This universal phenomenon is 
independent of species, cell type, and induction system and occurs early in the apoptotic 
process.  
HepB3 cells were selected to test the effect of arresting of miR-221 by sponge and to 
confirm the effect of chemically modified antimiR-221 alone or in combination with 
sorafenib on apoptosis, Muse™ Annexin V & Dead Cell Kit (Catalog#MCH100105)(EMD 
Millipore, Billerica, MA, USA) in Muse® Cell Analyzer: Mini, Affordable Flow 
Cytometry. This kit allows for the quantitative analysis of live, early and late apoptosis, 
and cell death on both adherent and suspension cell lines on the Muse™ Cell Analyzer. 
The software provides concentrations (cells/mL) for live, early apoptotic, late apoptotic, 
total apoptotic, and dead cells as well as Percentage of live, early apoptotic, late apoptotic, 
total apoptotic, and dead cells. The Muse™ System makes sophisticated fluorescent-based 
analysis. Annexin V is a calcium-dependent phospholipid-binding protein with a high 
affinity for PS, a membrane component normally localized to the internal face of the cell 
membrane. Early in the apoptotic pathway, molecules of PS are translocated to the outer 
surface of the cell membrane where Annexin V can readily bind them. The Muse™ 
Annexin V & Dead Cell Assay utilizes Annexin V to detect PS on the external membrane 
of apoptotic cells. A dead cell marker is also used as an indicator of cell membrane 
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structural integrity. It is excluded from live, healthy cells, as well as early apoptotic cells. 
Four populations of cells can be distinguished in this assay: 
• non-apoptotic cells: Annexin V (-) and 7-AAD (-) 
• early apoptotic cells: Annexin V (+) and 7-AAD (-) 
• late stage apoptotic and dead cells: Annexin V (+) and 7-AAD (+) 
• mostly nuclear debris: Annexin V (-) and 7-AAD (+) 
For this assay Hep3B cells were plated into 24-well culture plates at density of (1×10
5
) and 
infected with rAAV-miR-221sponge at MOI:100 or treated with miR-221 inhibitor oligos 
(100nM)and/or 5 and 10μM of sorafenib as well as vehicle-treated and untreated negative 
controls for 24 and 48h. Each condition was performed in triplicate .Cells were detached 
with trypsin. fresh serum containing medium was added to each well so final concentration 
was 1 x 10
5
  cells/mL. 100μL of cells in suspension transferred to a new tube and 100μL of 
the Muse™ Annexin V & Dead Cell Reagent was added to each tube. Samples were 
stained for 20 minutes at room temperature in the dark. After that assay was run in Muse™ 
Cell Analyzer according to its manual. 
3.10. Statistical Analysis 
 
Significance was determined with the two-tailed Student’s t test. A p-value threshold < 
0.05 was considered significant. All real time RT-PCR (assayed in triplicate), Western 
blotting, and transfection experiments were repeated twice, and reproducible results were 
obtained. Values were presented as the mean ± standard deviation (SD).   
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 CHAPTER 4 RESULTS 
 
4.1. PART I:  Development of Viral vector for  Inhibition 
of  miR-221 in HCC Cell Lines.  
 
4.1.1. Development of a Novel Sequestering Tools as microRNA 
Sponge for Inhibiting the miR-221.  
 
 Designing and Construction of miR-221Sponge  4.1.1.1.
 For this study the sequence of mature miR-221 (hsa-miR-221 MIMAT0000278) at URL: 
http://atlasgeneticsoncology.org/Genes/MIRN221ID44277chXp11.html, was considered 
for designing an antimiR-221. A sponge oligonucleotide contained 4 copies of the miR-
221 binding sites and 4 nucleotides spacer. Each MBS included a bulged site, as imperfect 
miRNA “bulged sponges” were reported to be more effective for the sequestration of 
miRNAs than sponges with perfect antisense sequence(177). The sequence of endogenous 
miR-221 and designed sponge is depicted in Figure 4.1. 
 
  
Figure 4.1. Schematic targeting of hsa-miR221 by sponge duplex oligonucleotide. miR-221 sponge designed with 
 4 copies of miR-221 binding site and 4  nucleotides spacer as imperfect sequences in the positions 12-15 of each MBS.  
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The designed sponge sequence equipped to overhangs that were compatible with the 
restriction endonuclease XbaI, so it enabled us for directional cloning of repetitive miRNA 
binding site sequences. The synthetic sponge oligos were assembled to make double-
stranded DNA duplexes. The annealed sponge was 113bp long and cloned into pGl3-
control using XbaI restriction sites for further sub clonning steps. 
 
4.1.2. Adeno-Associate Viral Vectors Expressing miR-221Sponge 
Along with Reporters GFP/ LUC Constructed for in vitro and in 
vivo Studies.   
 
We chose DJ serotype of AAV for this study. It is created by DNA family shuffling 
technology  and allowed highly efficient transduction in comparison with any other wild 
type serotypes, particularly in hepatocytes(198). pAAV vectors expressing miR-221sponge 
were constructed for the in vitro and  in vivo  studies. For in vitro study an AAV vector 
system to simultaneously express a transgene (miR-221 sponge) and GFP was engineered. 
Also in the interest of inhibiting miR-221 in vivo, GFP cassette of pAAV-IRES-GFP 
Expression Vector was replaced with Luciferase expressing cassette. By placing reporter 
genes under the same promoter as the transgene constructs, transgene expression and/or 
viral integration can be monitored by detecting the reporter signal. Presence of IRES 
sequence in the backbone of viral vector allowing simultaneous production of reporter 
gene and transgene from a single transcript and confers a high level of  translation. Figure 
4.2 showed the final genome packaged as rAAV-miR-221sponge. 
 
Figure 4.2. Schematic illustration of enclosing miR-221sponge oligo in AAV. miR-221sponge oligo inserted 
downstream of the IRES-GFP/Luc reporter cassette in the AAV expression vector and rAAV developed by triple 
transfection of expression and helper vectors into 293FTcells. 
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4.1.2.1. pAAV-miR-221Sponge-IRES-GFP Construction 
Construction of pAAV-miR-221sponge-IRES-GFP plasmid was a straightforward process. 
2ug of pAAV-IRES-GFP was excised with XbaI fast digest restriction enzyme (Fermetase) 
according to manufacturer's manual. Digested vector was subjected to the 
dephosphorylation step using 1µl Calf Intestinal Phosphatase (CIP) followed by incubation 
at 37°C for 1 hour. Dephosphorylation improved the probability of ligation of inset by 
preventing the self-ligation of vector. Complete digestion of vector were confirmed by 
agarose gel electrophoresis compared to undigested one. Digestion of pAAV-miR-
221sponge-IRES-GFP lined up vector and produced a 5983bp fragment (Figure 4.3). The 
desired fragment was recovered from the gel. Then, the miR-221sponge with XbaI cut 
overhanges ligated into cut and purified pAAV-IRES-GFP (see material and methods for 
details). The re-ligation efficiency of vector was evaluated by including the ligation 
control. The ligation products were then transformed into DH10β cells according to the 
chemically transformation methods using KCM buffer and allowed to grow overnight on 
ampicillin plates to select for cells containing plasmids. After overnight culture incubation, 
several randomly chosen ampicillin-resistant colonies were picked and dissolved in 100μl  
water. 1μl  of resolved colonies was used in a PCR colony reaction as template and the 
remains was grown in 3mL of LB broth for isolation of plasmid DNA (sigma mini-prep 
kit).  
Figure 4.3. Control digest of pAAV-IRES-GFP. Lane1: pAAV-IRES-GFP digested with XbaI .Lane1:The lined up 
vector was visible at 5983bp. Lane2: undigested pAAV-IRES-GFP vector. M: 1kb DNA marker. 
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Purified plasmid of the test samples were assayed for the presence of the 113bp sponge 
insert through excising  by XbaI . Analysis of  digested clones were visualized on 1% gel 
electrophoresis (Figure 4.4A). The correct orientation of the insert was verified by PCR. 
For colony PCR screening, pAAV-antimiR221-1339F and pAAV-antimiR221-1941R 
primers was used as a forward and reverse primer respectively. Sequences of primers used 
for verification of cloning steps are shown in the table 3.1. Primers were designed in 
Primer3Plus (http://www.bioinformatics.nl/cgi-bin/primer3plus/primer3plus.cgi/). The 
forward primer was picked up from a overlapping sequence of MCS and the 3' sequence of 
miR-221sponge as insert. So it could show the orientation of insert inside backbone. The 
PCR reaction was prepared in 10nM of dNTPs, 1X PCR buffer (Qiagen), 10μM of forward 
and reverse primers and 0.2μl of Taq polymerase (Qiagen) in a final volume of 12.5μl . 
PCR was performed in condition of 94°C  for 30 second ,54°C for 30 second followed up 
72°C  for 45 second during 30 cycles. Amplification of a 603bp PCR product was 
illustrated on agarose gel 1% in TAE 0.5x along with 1kb DNA ladder(Figure 4.4B). The 
positive clones were designed as pAAV-miR-221sponge-IRES-GFP.  
  
Figure 4.4.  Screening of recombinant pAAV-miR-221sponge-IRES-GFP construct. (A): Restriction digestion 
screening. Lane 1-6: Recombinant clones digested with XbaI , lane 7: positive control contains the same insert. lower arrow show  
the yielding 113bp insert fragment after digestion, M: 123bp DNA marker. (B): PCR screening. Lane1-3: clones in sense orientation 
of inset, PCR product contains a 603bp amplicon. Lane4: clone in antisense orientation. B: Blank sample, M: 1kb DNA marker. 
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We checked the efficiency of integrity of engineered vector before using it in the 
packaging step as virus. The 145 nucleotide ITR Sequences in the shuttle vector are 
capable of forming T-shape secondary structure and are the only cis elements that are 
required for AAV replication, packaging, integration, and rescue. The gene of interest 
along with a promoter to drive transcription of the gene usually are inserted between two 
inverted terminal repeats (ITR) that aid in concatemer formation in the nucleus after the 
single-stranded vector DNA is converted by host cell DNA polymerase complexes into 
double-stranded DNA. The integrity of ITRs can be verified by restriction digestion with 
SmaI. More than 80% digested can be considered as functional ITRs. Restriction digestion 
was done on 400ng of recombinant pAAV expression vectors  using SmaI (New England , 
Cell Biolabs) according to manufacturer’s instruction. The resulted fragments were 
visualized on agarose gel 0.8% in TAE buffer 0.5X. (Figure 4.5). The result shows 
complete digestion of ITR sequences implied that ITR sequences remains intact during 
cloning steps. 
 
 
Figure 4.5. Integrity of ITRs was verified by SmaI digestion. More than 80% digested can be considered 
as functional ITRs. The result shows complete digestion of ITR sequences implied that ITR sequences 
remains intact during cloning steps. (A): The expected features of bands after digestion designed in 
NEBcutter v2.0(http://tools.neb.com/NEBcutter2/). (B): pAAV-miR-221sponge and control vector cut with 
smaI. 
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4.1.2.2. pAAV-miR-221Sponge-IRES-Luc Construction 
In the interest of testing Anti-miRNA221 expression  in vivo, we positioned the miR-
221sponge sequences upstream of Luciferase gene as a reporter within the AAV shuttle 
vector. The IRES-GFP sequence in pAAV- miR-221sponge -IRES-GFP was substituted 
with the sequence of IRES-Luc from pIRES-Luc vector (Figure 4.6). 
 
 
          Figure 4.6. Schematic illustration of cloning steps of pAAV-miR-221sponge-IRES-Luc construction 
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pAAV-miR-221sponge-IRES-GFP and pIRES-Luc were double digested with XhoI and 
SalI restriction enzymes, according to the enzyme manufacturer’s instructions. Complete 
digestion were confirmed by agarose gel electrophoresis(Figure 4.7).  
A 4.7kb vector fragment from pAAV- miR-221sponge -IRES-GFP and 2.4kb IRES-luc 
cassette were recovered from the agarose gel. Luciferase expression cassette was ligated  
into the purified and dephosphorylated vector fragment using T4 DNA ligase(Roche) 
based on standard DNA ligation protocols. An aliquot of the ligation mixture was 
transformed into DH10β competent cells.  
  
Figure 4.7. Control digest with XhoI and SalI. Lane 1-4: Double digestion of pAAV-miR-221sponge-
IRES-GFP which produced a 4.7 kb vector fragment containing the AAV- ITRs miR-221sponge and a 
1.3 kb fragment containing the IRES-GFP cassette. Lane 5-8: Double digestion of  pIRES-Luc which 
cut  into 2.4kb  IRES-Luc fragment and 5.4kb  backbone fragment. M: 1kb DNA marker. 
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Identification of correct recombinant clones were done by PCR and restriction digestion 
analysis. Colony PCR screening was performed with primers lied down in luciferase 
sequence designated Luc 296F and Luc 764R as forward and reverse primers, respectively. 
The sequence of primers are summarized in table 3.1. Polymerase chain reaction was done 
according 94°C for 30'',  58°C for 30'' and 72°C for 30'' , repeated 30 cycles. Figure 4.8A 
shows the results of PCR screening after electerophoresis on agarose gel 0.8% in TAE 
0.5x. The positive recombinant clones from the previous step were screened for the 
orientation of insert by digestion with BamHI according to the standard protocol for 
digestion. The results were analyzed by gel electrophoresis alongside digested and 
undigested (Figure 4.8B). The positive clones with insert in correct orientation were 
designated  as pAAV-miR-221Sponge -IRES-Luc. 
Figure 4.8. Screening of recombinant pAAV-miR-221Sponge-IRES-Luc construct. (A): PCR 
screening. Lane1-10: PCR results of recombinant clones, positive clones contain a 497bp amplicon. B: 
Blank sample. P: positive clone ,M: 1kb DNA marker. (B): Analysis of recombinant clones through 
restriction digestion BI: The electrophoresis  of cut clones on 0.8% agarose gel. Lane with odd 
number: undigested recombinant clones, Lane with even number: compatible digested clones., M: 1Kb 
DNA marker M2: λhidIII ladder. BII: The expected features of pAAV-miR-221Sponge-IRES-Luc 
orientation of insert, digested with BamHI designed in NEBcutter 
v2.0(http://tools.neb.com/NEBcutter2/).as shown  incorporation of insert in sense orientation into 
backbone results in two 6.36kb and 0.8kb fragments.  
 
M  1   2   3  4   5   6   7  8  9  10  B   P 
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4.1.2.3. Transient Transfection of miR-221Sponge Inhibits miR-221 and 
Affect Regulation of its Targets.  
 Duel Luciferase Assay Reveals Down-Regulation of miR-221 Following 
Transient Transfection of miR-221Sponge  
To evaluate the suppressive activity of the sponge construct in vitro,  we asked whether the 
sequestration of miR-221 by the sponge products could disrupt the binding of miRNA to 
target sites in 3'-UTR of a target mRNA and thereby regulate its translation and/or 
abundance. Thus, we performed a dual luciferase assay using the luciferase reporter pGL3-
3'UTRp27, a vector in which the 3'-UTR of CDKN1B/p27 mRNA, a known target of miR-
221, was cloned downstream of the firefly luciferase gene(199). The renilla luciferase 
reporter vector pRL-TK was used as normalizer. These plasmids were co-transfected along 
with AAV vector harboring miR-221sponge and the control vector into HEK-293 cells. 
Transfection efficiency was monitored by GFP reporter expression (Figure 4.9). A scheme 
of the experiment is depicted in Figure 4.10A. We assumed that binding of the sponge to 
endogenous miR-221 could rescue the target site in 3'UTR of pGL3-3'UTRp27 vector and 
lead to an increased level of firefly luciferase activity. Firefly and renilla luciferase 
expression were measured 24 hours post-transfection and their ratio was used to calculate 
the relative luciferase activity. The average luminescence for each experimental sample 
was measured in triplicate. The ratio of control vector without sponge sequence was set at 
100%. Results showed that sponge construct were highly effective and revealed an 
increase of relative Luc expression by more than 2 times. Analysis of non-transfected 
control (NTC) showed no significant expression levels of lucifease in the absence of 
treatment. (Figure 4.10B). These results indicated that miR-221sponge could be used to 
sequester miRNA activity on target genes. 
Figure 4.9. Florescent microscopy showed 
transfection efficiency and GFP expression 
of pAAV-IRES-GFP expressing constructs 
in 293 cells (20X). (A) GFP expression of  
pAAV-miR-221sponge-IRES-GFP (B): White 
Balance feature of cells tranfected by pAAV-
miR-221sponge-IRES-GFP C: GFP 
expression of pAAV- IRES-GFP D: White 
Balance feature of cells tranfected by pAAV- 
IRES-GFP. 
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Figure 4.10. Inhibition of endogenous miR-221 by sponge construct in vitro. (A): A scheme of luciferase reporter 
assay that shows function of miR-221sponge. In the lack of sponge inhibitor, miRNA such as miR-221, loaded in RNA 
induced silencing complexes (RISCs), will bind to their endogenous targets and silence target genes and subsequently 
luciferase gene. In the presence of sponge transcripts, however, miR-221 will bind to the exogenous binding sites and 
be unavailable for silencing endogenous targets (3’UTR27), resulted in raising the luciferase expression. (B): Duel 
luciferase reporter assay. The control-GFP construct lack of sponge sequence was used as a control means 100% 
FF/renilla luc expression in the case of co-transfection with pGl3-3’UTRp27. miR-221sponges construct was able to 
relieve 3’UTRp27 via blocking by endogenous miR-221,as detected by increased luciferase activity around 200%. n=3, 
*p=0.001.  
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 Western Blot Analysis Validates Inhibitory Activity of miR-221Sponge  
 
Next we used western blot analysis to determine protein levels of a validated miR-221 
target genes upon its inhibition by sponge. We transfected HEK-293cells with 0,4μg 
pAAV.miR-221sponge and or pAAV.control without miR-221sponge expression cassette. 
For each transfection triple wells were considered. 48h after transfection cells were 
trypsinized and subjected for protein extraction as described in material and method. 
Blotting was performed for CDKN1B/p27 (BD Transduction Laboratories™, 610242, 
dilution 1:1500) a known target of miR-221. Beta-actin (Sigma Aldrich,A4700,dilution 
1:1000) was used for normalization purposes.  We observed 2.6 and 1.73 fold increase in 
CDKN1B/p27 protein level in comparison with non-transfected control and pAAV.control 
transfected cells, respectively (Figure 4.11). These results validated that miR-221sponges 
could be used to sequester miRNA activity on target genes. 
 
 
 
 
 
 
  
Figure 4.11. Western blot analysis of p27 target protein and beta actin. Transfection of HEK-293 cells 
by sponge expressing vector (pAAV.miR-221sponge) revealed 2.6 and 1.73 fold increase in CDKN1B/p27 
protein level compared to non-transfected control (NTC) and control construct without sponge 
(pAAV.control), respectively.  
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4.1.3. Adeno-Associated Viral Delivery of miR-221Sponge Suppresses 
the Endogenous Up-Regulated miR-221 in HCC cell lines 
 
rAAV for delivery of miR-221sponge produced through triple transfection of pAAV 
Expression Vector:pAAV-J:pHelper. Transfection efficiencies were visualized under 
fluorescence microscopy (Figure 4.12A,B). The most obvious sign of viral production was 
a color change in  the medium from red to yellow (compare to negative control). As viral 
production proceeds, some of the cells were round up and detach from the plate, and saw 
floating in the medium. In addition the population of cells started to distance each other so  
some big spaces were seen in cultured cells. Microscope photographs of AAV-producing 
versus non-AAV-producing cells were shown in Figure 4.12C,D. Generally, three days 
post-transfection was the optimal time to prepare AAV stocks. The ability of rAAV-miR-
221sponge-IRES-eGFP to knock-down endogenous miR-221 was assessed in Hep3B cells. 
For in vitro assay rAAVs were used to transduce cells at MOI:100. Uninfected and rAAV-
control infected cells were considered as controls. A TaqMan microRNA assay was 
employed to quantify miR-221 inhibition. As shown in Figure 4.13A, sponge against miR-
221 reduced expression of endogenous miR-221 by 45% and 42% in comparison with 
uninfected and control virus infected cells respectively. Furthermore, the protein level of 
CDKN1B/p27 exhibited a 2.2 fold up-regulation respect to uninfected cells. Also 1.46 fold 
increase was detected compared to rAAV-control (Figure 4.13B). These data demonstrated 
that rAAV provides an effective means to deliver a functional miR-221sponge.  
  
Figure 4.12. Development of 
rAAV. (A): Fluorescent features 
that shows triple transfection 
efficiency of pAAV-GFP 
Expression vector: pAAV-DJ: 
pHelper after 24 hours(10X). (B): 
White balance feature (10X). (C): 
Features of transfected cells after 72 
hours visualized under light 
microscope(10X) (D): non- 
transfected control culture (10X 
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Figure 4.13. Molecular assay of rAAV-sponge221-IRES-GFP. (A): Quantitative RT-PCR detection 
of miR-221 at 72 hours post infection of Hep3B cells with rAAV-miR-221sponge or rAAV-control, at 
MOI=100. Data are represented as mean values +/- SD from three replicates. rAAV-miR-221sponge 
induced a 45% and 42%  reduction in miR-221 expression level in comparison with uninfected (**: p-
value = 0.01) or rAAV-control infected cells (*: p =  0.02), respectively. (B): Western blot analysis of 
CDKN1B/p27 protein in cells infected with rAAV-miR-221sponge vector caused a 2.2 and 1.46 fold 
raise in p27/kip1 protein level in comparison with uninfected and rAAV-control, respectively. Beta actin 
protein was employed as reference normalize. 
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4.1.4. miR-199-Dependent Recombinant Adenovirus Express 
Functional miR-221Sponge in vitro. 
 
We hypothesized that the incorporation of miR-221sponge into Ad-199T (196) could 
provide the capability of inhibiting miR-221 specifically in HCC cells. Details of vectors 
construction are described in Materials and Methods and depicted in Figure 4.14A. To 
verify whether engineered adenovirus was able to express a functional miR-221sponge, we 
infected HepG2 cells with rAd-199T-miR-221sponge and rAd-199T control at MOI=10. 
Real Time TaqMan assay revealed that sponge decrease the level of miR-221 up to 75.5%  
and 55% relative to uninfected and control virus infected samples, respectively (Figure 
4.14B). To assess if the miR-221sponge expressed by rAd could modulate protein level of 
miR-221 target, we assayed CDKN1B/p27 levels by western blot analysis. Following 72 
hours of infection, increasing in the p27/Kip1 protein levels by ~8.5 fold was detected 
compared to uninfected and rAd control infected samples (Figure 4.14C). As designed 
(196), this adenoviral vector is expected to replicate only in the absence of miR-199, like 
in HCC cells. To verify that miR-199 could indeed regulate viral replication of rAd-199T-
miR-221sponge, the viral vector was used to infect cells of two different cell lines: HepG2, 
which do not express miR-199; HepG2/199, a derivative of HepG2 cells engineered to 
constitutively express miR-199a (196). To this purpose, 7.5×10
4
 cells of each cell line were 
seeded and infected with rAd-199T-miR-221sponge or control virus at MOI=10. The cells 
were harvested at various time points. The results shown in Figure 4.15 established that 
viral replication of rAd-199T-miR-221sponge was indeed miR-199-dependent. 
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Figure 4.14. Functionality of oncolytic recombinant adenovirus expressed microRNA sponge. (A) Scheme of 
the Ad-199T-miR-221sponge adenoviral vector, showing the location of the critical elements in the context of the 
adenoviral vector genome: CMV = CMV promoter; E1A = adenoviral E1A gene; miR-199T = target site for miR-
199a; E1B = adenoviral E1B gene; SV40p = SV40 early promoter; Luc = firefly luciferase gene; miR-221sponge. 
(B) Quantitative RT-PCR detection of miR-221 at 24 hours following infection of HepG2 cells with rAd-199T-
miR-221sponge or rAd-199T-control, at MOI=10. Data are represented as mean values + SD from three replicates. 
The results showed that miR-221 expression was inhibited 75.5% and 55% compared to uninfected (**: p-value = 
0.002) or control virus infected (*: p-value = 0.001) samples, respectively. (C) Western blot analysis of 
CDKN1B/p27 protein, confirmed an increase in target protein around 8.5 fold in comparison with uninfected or 
rAd-199T control virus in HepG2 cells. Beta actin protein was employed as reference normalize. 
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Figure 4.15. Replications of recombinant adenovirus is restricted to HCC cell lines. (A) Conditional 
replication of rAd-199T-miR-221sponge and rAd-199T control in HepG2 and HepG2/199 cells (Callegari, 2013). 
Results showed the inhibition of virus replication in miR-199-expressing cells, like the HepG2/199 cells, which 
mimic the situation of miR-199 expression in normal hepatocytes. (B) Time course of rAd vectors replication of 
in HepG2 cells. Data are represented as mean values +SD from three replicates. 
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4.1.4.1. miR-221Sponge Mediated Viral Delivery Induces Cell Apoptosis 
and Reduces Viability in HCC Cells  
To verify whether miR-221sponge is able to influence apoptosis and cell viability, we 
transduced hepatocellular carcinoma Hep3B cell line, which are characterized by high 
level of miR-221 expression with rAd-199T-miR-221sponge at MOI:10 as well as rAAV-
miR-221sponge at MOI:100. Comparable control rAd and rAAV infected cells were 
considered. We investigated the effect of miR-221 inhibition with 7-Amino-actinomycin D 
(7-AAD)/PE Annexin V staining. The results showed a highly increase in late apoptosis 
along with reducing the number of viable cells in rAd-199T-miR-221sponge infected cells 
compared to control virus infection condition. On the other hand an slightly increase in 
both early and late apoptosis consistent with decrease in number of viable cells were 
achieved for rAAV-miR-221sponge respect to rAAV-control infected cells. In this case no 
increase in number of dead cells was detected (Figure 4.16). 
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Figure 4.16 Effect of miR-221sponge mediated viral delivery on apoptosis of HCC HepB3 cells by Mini, Affordable 
flow cytometry. HepB3 cells were infected by rAd-199T-miR-221sponge at MOI = 10 and collected after 24 hrs, or 
rAAV-miR-221sponge, at MOI = 100 and collected after 72 hrs. Control  viruses were employed for comparison.  
Harvested cells were assayed for Annexin V and death markers to reveal the percentage of cells in early and late apoptotic 
as well as viable cells. A strong apoptotic effect was produced by rAd-199T-miR-221sponge in comparison with rAd-
199T control and a little increase in apoptosis was also induced by rAAV-miR-221sponge in comparison with rAAV 
control. 
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4.2. PART II: Development of  Adeno-Associated Viral 
Vector for  Restoration of  miR-199a in HCC Cell Lines.  
 
4.2.1. Recombinant AAV Plasmids Engineered for Expressing miR-
199a and GFP/ LUC Reporters for in vitro and in vivo Studies. 
4.2.1.1. pAAV-miR-199a-IRES-GFP Construction 
Construction of pAAV-miR-199a-IRES-GFP was done by substitution of miR-221 sponge 
sequence in already engineered pAAV-miR-221sponge-IRES-GFP with miR-199a 
sequences from pIRESneo2miR199(Figure 4.17).  
Figure 4.17. Schematic illustration of cloning steps of pAAV-miR-199-IRES-GFP construction 
 
pIRESneo2miR199 
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2ug of pAAV-miR-221sponge IRES-GFP and pIRESneo2miR199 were excised with XbaI 
and NheI restriction enzymes (Fermentase), respectively according to manufacturer's 
manual. Digested vector dephosphorylated using 1µl Calf Intestinal Phosphatase (CIP) 
followed by incubation at 37°C for 1 hour. Digested material in parallel with DNA ladder 
were run on  agarose gel and electrophoresis at 80V. for 45 min. Digestion of pAAV-miR-
221sponge-IRES-GFP produced a 5989bp fragment as vector. Insert excised from 
pIRESneo2miR199, with 647bp in length (Figure 4.18).  
 
 
 
 
Figure 4.18. Control digestion of pIRESneomiR199 and pAAV-miR-221sponge-IRES-GFP 
vectors .  A. pAAV-miR221sponge-IRES-GFP cut by XbaI . to provide source of vector in ligation 
step (5989bp band) M1: 123 DNA marker B.pIRESneomiR199 digested with NheI . 647bp miR199 
sequence was used as insert M2: 1kb DNA marker 
 
M2 
A 
B 
M1 
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The desired fragments was recovered from the gel. Then, the miR-199a with NheI 
overhangs ligated into the vector; pAAV-IRES-GFP. The chance of re-ligation of vector 
was evaluated by providing the ligation control samples. The ligated products were then 
transformed into DH10β cells by the chemically transformation methods using KCM 
buffer, then allowed colonies to grow overnight on ampicillin plates to select for cells 
containing plasmids. 
After an overnight culture incubation, several randomly chosen ampicillin-resistant 
colonies were picked and used in a PCR colony screening to detect the presence of the 
647bp miR-199a sequence. For colony PCR screening, miR-199NheI FWD and miR-
199NheI REV primers was used as a forward and reverse primer respectively. Sequences 
of primers used for verification of cloning steps are shown in the table 3.1. The PCR 
reaction was prepared in 10nM of dNTPs, 1X PCR buffer (Qiagen), 10μM of forward and 
reverse primers and 0.2μl of Taq polymerase (Qiagen) in a final volume of 12.5μl. PCR 
was performed in condition of 94°C  for 30 second ,68°C for 30 second followed up 72°C  
for 45 second during 30 cycles. Amplification of a 647bp PCR product was illustrated on 
agarose gel 1% in TAE 0.5x along with 1kb DNA ladder(Figure 4.19A). The positive 
clones were designed as pAAV-miR-199a-IRES-GFP. Restriction digestion also was done 
for screening of colonies harboring miR-199a sequence in correct direction.  Plasmid  
DNA was extracted using sigma mini-prep kit according to manuals of sigma company. 
300ng of DNA treated with 0.5l of NcoI Restriction enzyme(Fermentase). By this mean, 
sense clone could be differentiate from antisense clone by the size of bands visualized on 
the agarose gel(Figure 4.19B). 
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Figure 4.19. Screening of recombinant pAAV-miR199-IRES-GFP construct. (A): PCR screening. 
Lane1: 1kb DNA marker. Lane 2-11: PCR results of recombinant clones, positive clones contain a 647bp 
amplicon. 12: Blank sample. 13: positive clone 14: negative clone . (B): Analysis of recombinant clones 
through restriction digestion The electrophoresis  of cut clones on 0.8% agarose gel. Lane1: 1kb DNA 
marker. Lane 2,4,5,6 positive clones harboring insert in sense direction, Lane 3,7 clones harboring insert in 
antisense direction C: The schematic features of pAAV-miR-199-IRES-GFP . 
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4.2.1.2. pAAV-miR-199a-IRES-Luc Construction 
This cloning step was done by substitution of IRES-Luc with IRES-GFP fragment in the 
pAAV-miR-199a-IRES-GFP from step 4.2.1.1.  pIRES-Luc and pAAV-miR-199a-IRES-
GFP were double digested with XhoI and SalI restriction enzymes, according to the  
manufacturer’s instructions. Complete digestion were confirmed by agarose gel 
electrophoresis(Figure 4.20A).  
A 5282bp vector fragment from pAAV-miR199a-IRES-GFP and 2.4kb IRES-luc cassette 
were recovered from the agarose gel. Luciferase expression cassette was ligated into the 
purified and dephosphorylated vector fragment using T4 DNA ligase(Roche) based on 
standard DNA ligation protocols. The ligated product was transformed into DH10β 
competent cells.  Identification of correct recombinant clones were done by PCR and 
restriction digestion analysis as well. Colony PCR screening was performed with primers 
lied down in luciferase sequence designated for Luc 296F and Luc 764R as forward and 
reverse primers respectively. The sequence of primers are summarized in table 3.1. 
Polymerase chain reaction was done according 94°C for 30'',  58°C for 30'' and 72°C for 
30'' , repeated 30 cycles. Figure 4.20B shows the results of PCR screening after 
electerophoresis on agarose gel 0.8% in TAE 0.5x. The positive recombinant clones from 
the PCR step were screened for the orientation of insert by digestion with NcoI according 
to the standard protocol for digestion. The results were analyzed by gel electrophoresis 
alongside digested and undigested (Figure 4.20C). The positive clones with insert in 
correct orientation were designated  as pAAV-miR-199a -IRES-Luc. 
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Figure 4.20. Construction of pAAV-miR199-IRES-Luc.  AI. Double digestion of pAAV-miR-199-IRES-GFP 
and pIRES-Luc by XhoI and SalI. M1: 1kb DNA marker M2: λHindIII molecular weight ladder, Lane 1: Vector, 
lane 2: Insert. AII Quantification of vector and insert for ligation step. M: λHindIII molecular weight ladder, Lane 
1: Vector, lane 2: Insert. B:  PCR screening of recombinant pAAV-miR199-IRES-Luc construct. M1: 123 
DNA marker., B: blank, 1-20, clones amplified for Luc sequence with 497bp amplicone. Clones 8,10,13,15 and 20 
screened as positive. C: Restriction digestion Screening to verified positive clones contains insert at sense 
direction. The NcoI digested and undigested vectors are shown for each clone. M: 1kb DNA marker.Cl8 and Cl10 
were detected as positive clone with correct orientation of insert. 
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4.2.1.3. pAAV-IRES-Luc Construction 
To construct luciferase control plasmid, The IRES-GFP sequence in pAAV-IRES-GFP 
was replaced with the sequence of IRES-Luc from pIRES-Luc. XhoI and SalI overhangs 
were created by double digestion procedure to facilitate ligation of  insert into vector. 
Positive clones were selected by PCR (Figure 4.21A) and restriction digestion using NcoI  
( Figure 4.21B).   
 
Figure 4.21. Screening of recombinant pAAV-IRES-Luc construct. (A): PCR screening. Lane1-10: 
results of amplification of recombinant clones with luc_296_F and luc_764_R as forward and reverse 
primers respectively. positive clones produce a 497bp amplicon. B: Blank sample. M: 123 DNA marker. 
(B): Restriction digestion screening BI: The electrophoresis  of cut clones on 0.8% agarose gel. Lane 
with odd number: Digested recombinant clones, Lane with even number: Compatible undigested clones, M: 
1Kb DNA marker. BII: The expected features of bands after digestion of created clones with NcoI designed 
in NEBcutter v2.0(http://tools.neb.com/NEBcutter2/).As shown,  incorporation of insert in sense and 
antisense orientation into backbone results in different fragment in length.  
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Luciferase expression test demonstrated the expression of firefly (FF) luciferase reporter 
gene in pAAV-miR-199a-IRES-Luc and pAAV-IRES-Luc as well as pre-constructed 
pAAV-miR-221sponge-IRES-Luc. A Renilla luciferase vector (pRL-TK) was used to 
normalize experimental variability caused by differences in cell viability or transfection 
affiency. Firefly and renilla luciferase were measured by employing a Promega Dual-
Luciferase® Reporter Assay System according to the supplemental manual (see material 
and methods for details). The results showed that pAAV vectors contains miR-221sponge 
or miR-199a and luc cassettes moderately expressed luciferase by 2.9 and 2.4 fold to 
NTC(non transfected control) respectively(pvalue: 0.0014, 0.05). Also using  engineered 
pAAV-IRES-Luc control vector we could detected highly expression of luc by 17.1 fold to 
NTC (pvalue: 0.0011) (Figure 4.22). 
 
 
 
Figure 4.22. Fold changes of average FF/renilla Luminescence of pAAV-miR-199-IRES-Luc , pAAV-IRES-Luc and 
miR-221sponge-IRES-Luc  respect to non-trasfected control (NTC). Each histobar represents the mean values ±SD of 
triplicate technical  observations. Error bars dedicated standard error. The NTC control showed the lowest activity of 
luciferase. The pAAV-miR-221sponge-IRES-Luc, pAAV-miR-199-IRES-Luc and pAAV-IRES-Luc engineered constructs 
were able to express luciferase by 2.9 (*p=0.0014), 2.4 (**p=0.052),  and 17.1 (0**p=0.0011)  to NTC control 
respectively.  
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4.2.2. Recombinant Adeno-Associated Virus Developed to regulate 
the expression of  miR-199a. 
pAAV vector harboring the coding sequence of miR-199a was packaged into adeno-
associated vector by triple transfection methods( see material and methods for details).To 
verify whether engineered adeno-associate virus was able to express miR-199a, we 
infected HepG2 cells with rAAV-199 and rAAV-control (rAAV-IRES-GFP) at MOI=500.  
Infected cells were harvested after 72h post-infection .Total RNA was isolated by using 
Trizol (see material and methods) and followed for purification using miRneasy kit. Real 
Time TaqMan assay with specific primer and probe for miR-199a revealed increasing 
expression level of miR-199a up to 92.1% (pValue=0.001) relative to control virus infected 
samples. The level of miR-199a expression in AAV-control infected cells was resulted the 
same level as uninfected HepG2(Figure 4.23). 
 
 
 
 
Figure 4.23. Functionality of rAAV expressed microRNA 199. Quantitative RT-PCR 72 hours following 
infection of HepG2 cells with rAAV-199 or rAAV-control, at MOI:500. Data are represented as mean values + SD 
from three replicates. The results showed that miR-199 expression was 92.1%  higher compared to  control virus 
infected (p-value = 0.0001).  
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4.2.2.1. miR-199a Expression Promotes Apoptotic Cell Death and 
Reduces Viability in HCC Cells 
 
The hepG2 cells which characterized as HCC cell line with down-regulated level of miR-
199a was transduced with rAAV-199 at MOI: 500. Comparable control rAd and rAAV 
infected cells were considered. The experiment was done in triplicate. We investigated the 
effect of miR-199a restoration on viability and apoptosis of HepG2 cells. Apoptosis were 
done through 7-Amino-actinomycin D (7-AAD)/PE Annexin V staining (Figure 4.24 A). 
The results showed a decrease in viability by around 51% which accompanied with 64.2% 
increase in the late apoptosis Phase(Figure 4.24 B). In this case no considerable increase in 
number of dead cells was detected. This results validated the regulation of miR-199a 
expression in HCC cell lines with low level of miR-199a could affect on cell proliferation 
and pull them to programmed death. Besides we checked the different concentration of 
AAV (from MOI: 10 to 10000) used for infection to optimize the most functional titer of 
virus. Function of  rAAV-199 virus in different titers were compared using viability and 
apoptosis analysis. We showed the functionality of recombinant virus in cellular level is 
consistently related to titer of virus infected(Figure 4.24C). 
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Figure 4.24. Cellular viability and apoptosis assay for HCC cells infected with  rAAV-199. (A): HepG2 cells infected with 
rAAV and control virus at MOI: 500. 72h post infection, Viability and Apoptosis was determined by Mini Affordable flow 
cytometry.(B): Restoration of miR-199 caused  the the 51% decrease in viability and 64.2% increase in apoptosis (* 
pvalue<0.05),  in HepG2 cells infected by rAAV-199 compared to control virus. (C): Functionality of engineered rAAV-199 is 
a relationship of titer of virus for infection. By increasing the concentration of virus used for infection a decrease in viability 
and an increase in apoptosis was observed. 
 
* 
* 
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4.3. PART III. Investigation of Combined Anticancer 
Effects of AntimiR-221/mimics miR-199a and Sorafenib 
through in vitro and in vivo Studies. 
Lab of professor Negrini recently validated the tumor-promoting effect  of  miR-221, by 
showing that in vivo delivery of antimiR-221 oligonucleotides leads to a significant 
reduction of the number and size of tumor nodules(176). In addition,  the multi-kinase 
inhibitor sorafenib has been approved for the therapy of advanced HCC(200). In this study 
we assessed the combination of anti-miRNA approach, like chemically modified antimiR-
221 and sorafenib as a novel therapeutic strategy to potentiate growth inhibitory function 
of sorafenib in HCC cells. Also, as down-regulation of miR-199a in HCC was frequently 
reported (124) and important modulator of cell cycle and cell proliferation like mTOR and 
c-met are in the list of proven target for miR-199a, we decided to test if  restoration of 
miR-199a level, sensitize cells towards drug treatment. We combined miR-199a 
oligonucleotide treatment with sorafenib and compared with efficacy of miR-199a and 
sorafenib alone.   
4.3.1. Sorafenib Decreases Cell Viability and Promotes Apoptosis in 
HCC Cell Lines 
The viability and apoptotic effect of sorafenib were examined using two different HCC cell 
lines, HepG2 and Hep3B. Cells were seeded in a 96-well plate and treated with increasing 
doses of sorafenib from 0.1 to 10μM which is the clinical relevant dose of sorafenib 
treatment. The effect of sorafenib on cell proliferation was measured by CellTiter-Glo® 
Luminescence assay and on apoptosis by using Caspase-Glo® 3/7 Assay after 48 hours 
exposure to drug (Figure 4.25). In both cell line which were tested, sorafenib treatment 
conducted decrease in viability of cells in a dose-dependent manner (Figure 4.26A).  
Induction of caspase3/7 apoptosis by sorafenib was further evaluated in the same treated 
wells. In HepG2 cell line, results showed apoptosis was increased in the presence of 0.01, 
0.1 and 1μM of sorafenib respect to non-treated(NTC) and solvent control (CTL). 
However in higher dose of sorafenib, since the majority of cells go through dead phase, the 
results were not significant. Induction of apoptosis, in Hep3B cells, appeared to correspond 
in rising in the drug-dose (Figure 4.26B). All together these data indicated that sorafenib 
can inhibit proliferation and induced caspase3/7 apoptosis in hepatocellular carcinoma in 
vitro. 
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Figure 4.25. Morphological changes induced by different concentration of sorafenib exposure for 48h (A): HepG2 
cell line. (B): Hep3B cell line 
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Figure 4.26. Sorafenib decrease viability and induces apoptosis in HCC cells. Sorafenib was added to 
HepG2and Hep3B cells and cultured for 48 hours in complete culture medium in the presence of 10% FBS. 
Fold changes of media of each triplicate treatment were analyzed and considered as results. (A): inhibition of 
cell proliferation. (B): Induction of apoptosis via caspase3/7 activity analysis. 
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4.3.2. HCC Cell Lines Show Variable Sensitivity to Sorafenib  
 
We decided to determined IC-50 values of sorafenib in HCC cell lines, at which 50% of 
the cells were growth-inhibited compared with control. We hypothesized that for detecting 
the synergistic effects, it is easier to use sub-IC50 concentrations of sorafenib in 
combination with constant concentration of antimiR-221/mimics miR-199a oligos. 
Sorafenib dose-dependent inhibition of cell proliferation assessed in HepG2 and Hep3B 
cell lines. Cells were plated in 96-well plates (10,000 cells per well) and exposed to 0.01, 
0.1 ,1 ,3, 5 and 10μM of sorafenib. Cells were tested using CellTiter-Glo® Luminescence 
Cell Viability Assay kits (Promega Corporation) as assays that require only a few minutes 
to generate a measurable signal (e.g., ATP quantization or LDH-release assays) provide 
information representing a snapshot in time and have an advantage over assays that may 
require several hours of incubation to develop a signal (e.g., MTS or resazurin). The cells 
were incubated with sorafenib for 24 and 48 hours. Cremophor EL/95% ethanol (50:50) at 
a concentration equal to that of 5μM drug-treated cells was used for checking the effect of 
drug-solvent. The results were obtained in two independent experiments, each of which 
was performed in triplicate. Fold changes of the number of viable cells respect to non-
treated cells (NTC) were plotted to varies concentration of sorafenib. As shown in Figure 
4.26, sorafenib decreased the number of viable HepG2 cells dose-dependently with an 
IC50 of around 2μM and more than 10μM for Hep3B cells after 48h drug-exposure. 
Interestingly, sorafenib exhibited a much stronger inhibitory effect on the survival of 
HepG2 respect to Hep3B as evidenced by its lower IC50 values. 
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Fig. 4.27. IC50 determination for sorafenib in HepG2 and Hep3B cells. Cells were cultured for 
48h in the presence of different concentrations of sorafenib from 0.01μM to 10μM. After which 
viable cell numbers were determined using cell titer Glo luminescence assay. For HepG2 the IC50 
was around 2μM, for Hep3B,  IC50 showed higher value shifted towards 10μM.  
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4.3.3. AntimiR-221/mimics miR-199a Oligos Have Synergistic 
Effect with  Sorafenib in HCC Cell Lines 
 
We further investigated whether down-regulation of an established oncomiR “miR-221”  
modulate the response of hepatocellular carcinoma cells to a novel drug that is potentially 
feasible for use in the clinic “sorafenib”. Also we tested the efficiency of up-regulation of 
miR-199a as anti oncomiR in HCC alone or in combination with sorafenib. This possibility 
was explored through cellular and molecular assay in HCC cell lines, as well by in vivo 
assay for miR-199a. 
4.3.3.1. Cell viability in HCC Cell Lines Reduce by Combination 
Therapy of AntimiR-221 as well as mimics miR-199a and sorafenib  
To determine if combining AntimiR-221/miR-199a and/or sorafenib  leads to  synergistic 
effect on cell survival in vitro,  HepG2 or Hep3B cells (10,000 cells per well in 96-well 
plates) were incubated with 100nM of antimiR-221/premiR-199a-3p oligonucleotides and 
sub-IC50 concentrations of sorafenib alone or in combinations. Non-transfected (NTC), 
vehicle (Solvent+lipofectamin2000) or scrambled oligonucleotide controls were 
considered for establishment and verification of final effects. Cell survival was measured 
by CellTiter-Blue® fluorescent assay after 24h and 48h of transfection and/or drug 
exposure for Hep3B and HepG2, respectively. The time points of treatment were optimized 
in independent experiments between 12, 24 and 48 hours which established by microscopic 
as well as cell viability and apoptosis analysis (Data not shown). A shorter time of oligo 
and/or drug exposure that was related to much stronger inhibitory effect of antimiR-
221/miR-199a was obtained in Hep3B respect to HepG2, as the most profound effects 
were achieved at 24h for Hep3B, comparing 48 h for HepG2. Data were obtained in 
independent experiments, each of which was performed in triplicate. Fold changes of the 
media fluorescent detected in each treated wells respect to non-treated/transfected wells 
(NTC) were used to detect the effect of co-treatment of antimiR-221/pre-miR-199a and 
sorafenib. As shown in Figure 4.28 combining of antisense miR-221 oligos with sorafenib 
could enhance the antitumor effect of sorafenib through declining the number of viable 
HCC cells in vitro . Figure 4.28 A shows the efficacy of transfection . Viability of HepG2 
cells in the presence of antimiR-221 and sorafenib poorly decreased by 5% ,p value= 
0.048, n=3 (Figure 4.28B) The cell titer value in untreated Hep3B significantly decreased 
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more than to 21%,30% and 44% in 5 and 10μM of sorafenib and 100nM antimiR-221 
treated cells respect to NTC (P < 0.005,n=3), respectively. While in co-treated Hep3B cells 
(antimiR-221+sorafenib) 36% and 28%(P < 0.005,n=3),  decrease in the number of viable 
cells was detected respect to 5 μM and 10μM Sorafenib single treatments (Figure 4.28C). 
Scramble and vehicle controls did not show significantly anti-proliferative effects. 
Figure 4.28. AntimiR-221 and/or sorafenib inhibit proliferation of HCC cells.( A) efficiency of transfection revealed 
under florescent microscope (10x). Results were shown as percentage of fold changes of median luminescence activity to 
non treated (NTC) control, Pvalue‹0.05 n=3. Vehicle (Solvent of sorafenib+lipofectamine 2000) (B): Cell viability assay in 
HepG2 cell line.(C): Cell viability assay in Hep3B cell line. 
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premiR-199a instead decreased the number of viable cells by 16% regards to un 
transfected control. This effect were 21% and 30% (P < 0.005,n=3), for sorafenib treatment 
at concentration of 5 and 10μM( Figure 2.28). Combining premiR-199a and sorafenib 
treatment showed to be more effective than each treatment alone. We detected 28% (p 
value=0.042,n=3) and 22%(p value=0.048,n=3)  reduce in viability of hep3B cells for 
premiR-199a combined with 5 and 10μM of sorafenib respect to sorafenib treated alone, 
respectively(Figure 4.29). 
 
 
 
 
Figure 4.29. PremiR-199 and/or sorafenib inhibit proliferation of HCC cells. Results were shown as 
percentage of fold changes of median luminescence activity to non treated (NTC) control, Pvalue‹0.05 n=3. 
Vehicle (Solvent of sorafenib+lipofectamine 2000) . 
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4.3.3.2. Combination Therapy of AntimiR-221/miR-199a Oligos and 
Sorafenib Increase  Caspase-3/7 Apoptosis in HCC Cells. 
To assess how combining antimiR-221/premiR-199a oligos and sorafenib, affect cell 
apoptosis, we examined activation of caspases 3 and 7 in HCC cells. Caspase-3/7 activity 
was measured immediately after the detection of CellTiter-Blue® Cell Viability Assay 
(described above) on the same treated wells, by adding Caspase-Glo® 3/7 assay reagent at 
the established time after transfection and/or sorafenib treatments into HepG2 and hep3B 
plated cells. The most profound apoptotic effects were achieved at 48h for HepG2 and 24 h 
for Hep3B. Analysis of apoptosis in HepG2 (Figure 4.30A) revealed that co-treatment of 
antimiR-221 with 1μM of sorafenib induced a significantly higher increase in 
luminescence measurement related to activity of caspase 3 and 7 proapoptotic enzyme by 
more than 72% to sorafenib 1μM and 25% to antimiR-221 oligos single treatments (P < 
0.005,n=3). The  mean caspase 3/7 apoptosis rates respect to untreated control were 
detected as 20.47% ,66.95% and 92.28% for 1μM of sorafenib and 100nM antimiR-221 
and their combination(P < 0.005,n=3). Scramble and vehicle controls did not show 
significantly increase in apoptosis. Apoptosis rate for premiR-199a in combination with 
sorafenib showed increase of 19% and 44% compared to premiR-199a and 1μM sorafenib 
single treatment, respectively(P < 0.005,n=3).. In Hep3B(Figure 4.30B), antimiR-
221/premiR-199a transfected cells were treated with the combination of different 
concentration of sorafenib. A moderate dose-dependent caspases-3/7 activation was 
observed in Hep3B cells exposed to 5μM and 10μM sorafenib alone . However a 
substantial effect was observed in presence of 100nM of antimiR-221 alone. Analysis of 
apoptosis attributed to antimiR-221 co-treatment with sorafenib in Hep3B revealed 
increased induction of apoptosis considering sorafenib single treatments but not to co-
treatment with antimiR-221, it was related to extensive effects of antimiR-221 that they not 
only stopped proliferating, but they actually killed cells during 24-36 h. Using premiR-
199a single treatment induce apoptosis 10% more than sorafenib 10μM regards to NTC. 
However co-treatment of premiR-199a and sorafenib showed higher effect as 119% and 
86% increase in apoptosis respect to 5 and 10μM of sorafenib respectively(P < 0.005,n=3). 
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Figure 4.30. Apoptosis induction were detected via caspase3/7 activity following  treatment of HepG2 and Hep3B. 
Results are displayed  as percentage of fold changes fluorescence activity respect to  non treated control(NTC). The test 
was done in triplicate and pvalue‹0.05 was considered as significant. Vehicle (Solvent of sorafenib+lipofectamine 2000) 
(A): Caspase 3/7 assay in HepG2 cell line. (B): Caspase 3/7 assay in Hep3B cell line. 
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4.3.3.3. Annexin V Apoptosis Assay Validates the Synergistic Effect of  AntimiR-
221 Oligos and Sorafenib. 
The Muse™ Annexin V and Dead Cell Assay is based on the detection of 
phosphatidylserine (PS) on the surface of apoptotic cells, using fluorescently labeled 
Annexin V in combination with the dead cell marker, 7-AAD (see material and methods 
for details). Induction of apoptosis by combination of antimiR-221 and sorafenib was 
further validated  by Annexin V and Dead Cell Assay. We exposed HepG2 and Hep3B 
cells which were seeded in 24 well plate to constant molarities of miR-221(100nM) and 
different established concentration of sorafenib just below their IC50. After 12,24,48h of 
drug exposure, we assessed the percentage of apoptotic cells employing Muse™ Annexin 
V & Dead Cell Kit. In HepG2, effects became apparent from time point 48h, but in Hep3B 
we saw the apoptotic effect earlier and harvested them at 24h(Figure 4.31).  
Figure 4.31. Muse Annexin V and Dead Cell analysis .1*10
5
 Hep3B cells seeded in 24 well plate. The day after 
cells were treated with sorafenib in defined concentration and /or AntimiR221 with final concentration at 100nM 
and incubated for 12, 24 and 48hours. The results of staining 1*10
4 
cells/ml with Fluorescent Annexin V and 7-
AAD dead marker dyes were visualized in muse mini flowcytometry(see material and methods for details). The 
final quantitative analysis of live, early and late apoptosis, and cell death for 12 and 24 hours were shown here. 
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Induction of apoptotic effects of single agent treatments vs. control, as well as 
combinations vs. single agents reached statistical significance in HepG2 as well as Hep3B 
cells(Figure 4.32). 
 
Figure 4.32. Apoptosis induction were detected using fluorescently labeled with Annexin V in combination with the 
dead cell marker, 7-AAD following  treatment of HepG2 for 48h (A) and Hep3B for 24h (B). Results are displayed  as fold 
changes to non treated(NTC) or vehicle control (Solvent+lipofectamine 2000).( *) pvalue ‹0.05  for anti221 transfected alone 
or in combination with sorafenib respect to control(NTC or CTL) .(**) pvalue ‹0.05 for combination treatment respect to 
AntimiR-221 trasfected cells alone.  
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Taq man real time assay was also performed to explain that the cellular anti-proliferative 
and apoptotic effects of antimiR-221 and/or sorafenib might be ,at least in part, 
consequence of down-regulating of endogenous miR-221.Using iCycler iQ5 optical system 
software (BioRad, Hercules, CA, threshold cycle (beginning of the PCR exponential 
phase) values were analyzed for miR-221 target and amplified U6sn RNA. The levels of 
miRNAs expression were normalized after subtracting the Ct value of the U6sn RNA 
internal control from that of miR-221 Ct value for samples In order to compare the levels 
of miRNA expression between different treated samples . The relative amount of target 
miR-221 was expressed as a relative ratio versus those of U6sn RNA. Experiments were 
conducted in triplicate. Probability values of <0.05 were considered significant(Figure 
4.33) 
 
Figure 4.33. Real time TaqMan assay for miR-221. Comprehensive silencing of endogenous miR-221 in samples which 
tranfected in the presence of antimiR-221oligos were validated as relative to control. 
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4.3.3.4. AntimiR-221 Induces Cell Cycle Arrest in Hep3B Cells 
Next we examined the effect of combination of antimiR-221 and sorafenib by cell cycle 
analysis. We transfected Hep3B cells with antimiR-221 oligo(100nM). After 48 h cell 
cycle analyzed with Muse™ Cell Cycle Kit Catalog No. MCH100106 according to 
instructor’s manual.  The value of cell populations at different stages of cell cycles are 
listed within the panels (Figure 4.34). The results showed a 1.4 and 1.2 decrease in S phage 
of cells treated with antimiR-221 oligo+sorafenib respect to control and cells treated with 
sorafenib, respectively.    
 
 
Figure 4.34. cell cycle analysis of AntimiR-221oligoes transfected Hep3B in combination with sorafenib. 
A decrease in S Phage accompanied with little increase in G1 phase was observed in Cells treated with 
AntimiR-221oligoes+5μM of Sorafenib compared to Control and sorafenib treated cells. 
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4.3.4. In vivo Anti-tumor Activity of mimics miR-199a  Restoration  
Alone and in Combination with Sorafenib. 
We next investigated the effect of miR-199a treatment alone or in combination with 
sorafenib in miR-221 transgenic (TG221) mouse, which is predisposed to the development 
of liver cancer. A highly significant(p value=0.006) decrease in number of nodules was 
detected following 9 injections (3times a week for 3 weeks) of mimics miR-199a oligos 
regards to control mice(Fig.4.35A) that seems be as effective as clinical dosage of 
sorafenib. The combination of miR-199a and sorafenib did not show higher effect than 
single Ones. Furthermore, we measured the diameter of tumor nodules (Fig. 4.35B). The 
results showed a decrease in size of tumor in groups treated with mimics miR-199a oligos 
regards to control group although it was not statistically significant, suggesting a need for 
increasing the number of cases in further experiment. Sorafenib as well as combination 
therapy did not significantly decrease the size of tumor nodules compared to control.   
 
  A 
B 
Figure 4.35. in vivo assessment of 
miR-199a restoration alone or in 
combination with sorafenib. (A). 
Number of tumor nodules. 8,508 ± 
2,385 (p value=0.006)  difference in 
Mean ± SEM of mimics miR-199a and 
control groups showed achieving  highly 
decrease in number of tumors in miR-
199a based therapy that was accordance 
with sorafenib and their combination 
therapy. (B). Average diameter of 
tumor nodules(μm).  
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4.4. PART IV: Assessment of Novel Cancer-Associated 
Targets of miR-221 
To identify genes controlled by miR-221, we compared gene expression profiling of SNU-
398 cells transfected with miR-221 precursor vs. SNU-398 cells transfected with negative 
control (NC2, Ambion). This cell line was chosen because it expresses low level of miR-
221. From the list of genes identified by Sylamer and the list of path-ways significantly 
affected by miR-221, we focused our attention on genes involved in cell proliferation and 
apoptosis regulation to individually validate them as miR-221 targets. They included the 
cell cycle regulators retinoblastoma 1 (RB1) and WEE1, the pro-apoptotic gene Apoptotic 
Peptidase Activating Factor 1 (APAF1), CCCTC-binding factor (CTCF), a transcriptional 
repressor and Annexin A1 (ANXA1). In addition, we also investigated Fas Ligand 
(FASLG), which contains a miR-221 target region in its 3UTR, but was not within the 
Sylamer-derived- 602 genes list. The genes studied are listed in Table 4.1. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 4.1.Genes individually validated as miR-221 targets 
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To validate potential miR-221 target genes, we first performed luciferase assays. We 
cloned a portion of the 3UTRs containing miR-221 target sequences into a psiCheck-2 
reporter vector, downstream the luciferase reporter gene. We assayed the luciferase activity 
in the presence or absence of added miR-221 mimics in three different cell lines: HEK-293 
(embryonic kidney derived cells) and two hepatocarcinoma derived cells (SNU-398, 
HepG2). The reporter vector constructs were transfected into cells together with miR-221 
precursor or negative control (NC2). We found that miR-221 induced a significant 
decrease in luciferase activity of all the vectors containing 3UTRs of genes identified 
through the Sylamer approach. Instead, no change in luciferase activity could be detected 
for the psiCheck-FASLG 3UTR vector (Figure 4.36A).  
TheabilityofmiR-221toinduceadecreaseinRB1,APAF1, ANXA1, WEE1, and CTCF 
expression was further demonstrated by measuring the relative amount of their mRNAs in 
SNU-398 and HepG2 cell lines. We found a significant decrease (p-value< 
0.003) of RB1 mRNAs in both cell lines transfected with miR-221 (−64% in SNU-398 and 
−72% in HepG2); similarly, we found 26 and 42% decrease in APAF1 mRNA level, 
respectively, in SNU-398 and HepG2 (p-value<0.015); miR-221 caused a decrease of 38% 
(SNU-398) and 77% (HepG2) of ANXA1 mRNA (p-value<0.018); WEE1 mRNA was 
44% (SNU-398) and 61% (HepG2) less expressed in presence of microRNA (p-
value<0.013) and CTCF mRNA showed a 38% decrease in miR-221 transfected SNU-398 
cells (p-value=0.006), while in HepG2 we found a slight (but not significant) decrease 
(Figure 4.36B), meaning that specific cell background could modulate microRNA effects 
on target genes. Finally, protein expression analyses revealed that miR-221 could indeed 
decrease the levels of RB1, WEE1, APAF1, and ANXA1 proteins in SNU-398 cells; 
conversely, an oligonucleotide antimiR-221 induced their increase in SNU-398/miR-221 
stable clone (Figure 4.36C). We could not test CTCF protein, because available antibodies 
produced poor quality results. 
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Figure 4.36 Validation of individual miR-221 target genes. 
(A). Luciferase assays were performed in Hek293, SNU-398, and HepG2 cells transfected with miR-221 or negative control (NC2), together 
with psiCheck luciferase vectors containing portions of the 3 UTR of the investigated genes placed downstream the renilla luciferase gene. 
The renilla luciferase activity was normalized on firefly luciferase activity. Compared to NC2 controls, miR-221 induced a significant 
decrease in luciferase activity of the vectors containing the RB1, APAF1, ANXA1, WEE1, and CTCF 3 UTR. In contrast, no change in 
luciferase activity could be detected for the FASLG 3UTR-luciferase vector and the psiCheck control vector.**p-value≤ 0.01;***p-
value≤0.001.(B). RB1, APAF1, ANXA1, WEE1, and CTCF mRNA expression was measured in SNU-398 and HepG2 cells following 
transfection with miR-221 or NC2 using Real Time PCR. A significant reduction in mRNA levels was detected for all the investigated genes, 
with the exception of CTCF mRNA in HepG2 cells.*p-value≤0.05;**p-value≤0.01;***p-value≤0.001.(C)Protein expression levels were 
assessed by Western blot analysis. miR-221 induced a decrease in RB1, APAF1, ANXA1, and WEE1 proteins in SNU398 cells, while 
transfection of antimiR-221 into SNU-398/miR-221 stable clone induced an increase in target protein levels.Numbers indicate the fold change 
decrease or increase of proteins expression in miR-221 or antimiR-221 transfected cells vs. the respective controls. Protein expression levels 
were normalized vs.β-actin expression. 
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Hepatocellular carcinoma (HCC) is one of the most common solid tumors. More than 
626,000 cases of HCC-related deaths are reported yearly worldwide, which ranks it as the 
third most common of death from cancer(201). It is also one of the deadliest disease, as the 
annual incidence almost equals the annual mortality, and its incidence is on the rise in 
developed countries(201). Among all the therapies available for HCC, the surgical 
resection and liver transplantation are currently best curative options to treat liver cancer. 
However the high frequency of tumor recurrence and metastasis after curative resection is 
the major obstacle in the process of HCC treatment. Statistical analysis show that the 
survival rate of patients who have had a resection is 30% to 40% at 5 years(202). 
Chemotherapy and radiotherapy, the two conventional therapies applied in the treatment of 
cancer, also get an unfavorable score because of the resistance of HCC. Moreover, 
occurrence of HCC often coupled with liver dysfunction, leads to restrict the use of 
conventional chemotherapeutics, as well as there is more or less non-selective toxicity with 
significant systemic side effects(6). 
Emergence of miRNAs as a new class of gene regulators and their well-known role in 
cancer progression has opened new avenues for therapeutic discovery. miRNAs potently 
influence cellular behavior through the regulation of extensive gene expression 
networks(203). Many experimental and clinical studies revealed that the aberrant 
expression of miRNAs is associated with initiation, progression and metastasis of 
cancers(73, 83). Numerous reports have demonstrated that alterations in intracellular 
miRNAs correlate with liver diseases(14, 199, 204). 
Among miRNAs deregulated in HCC, miR-221 and miR-199a are of particular interest(83, 
103, 142, 204). As in highly aggressive HCCs, miR-221/-222 was among the most up-
regulated of all miRNAs studied(79). miR-221 over-expression inhibits apoptosis of 
hepatocytes and delays fulminant liver failure(205); It has also been shown that miR-221 
accelerates hepatocyte proliferation during liver regeneration(206). miR-221 stimulates the 
onset of tumors and promotes tumor progression, significantly shortening the median time 
to death in a mouse liver cancer model(103).  
miR-199a is the third most highly expressed miRNA which is consistently decreased in 
HCC, and its decrement significantly correlates with the malignant potential and poor 
prognosis of HCC(114, 120). Decreased expression of miR-199a-5p also contributes to 
increased cell invasion by functional deregulation of DDR1 activity in HCC(207). 
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Another study in HCC showed that the decrement of miR-199a-3p significantly correlated 
with poor survival of patients. It could target tumor-promoting PAK4 to suppress HCC 
growth through inhibiting the PAK4/RAF/MEK/ERK pathway(120).  
Therapeutic modulation of a single miRNA may affect many pathways simultaneously to 
achieve more clinical benefit(185). Hence targeting aberrantly expressed miRNA is logical 
and attractive. Available evidences indicate that miR-221 as well as miR-199a are potential 
target for non-conventional treatments against HCC(99). 
Over-expression of miR-221 in a transgenic mouse model led to a strong predisposition to 
the development of liver cancers, whose number and size could be significantly reduced by 
the delivery of antimiR-221 oligonucleotides(156). For miRNA inhibition, miRNA 
antisense oligonucleotides and miRNA sponges have been described(155). Antisense 
oligonucleotides provide a transient inhibition of microRNA. Vector-encoded miRNA 
sponges are instead expected to inhibit miRNA activity over a longer period of time. 
Restoration of miR-199a-3p in Papillary Thyroid Carcinoma cells reduced MET and 
mTOR protein levels, impaired migration and proliferation and induced lethality through 
an unusual form of cell death. 
This study explored the feasibility of regulation of miR-221 and miR-199a levels as novel 
therapy in HCC. We firstly showed the practicability of a novel miRNA sequestering 
methods ”MicroRNA Sponge” for regulating the level of miR-221,  noticeably up-
regulated in HCC. In addition, we evaluated the restoration of miR-199a mediated adeno-
associated viral delivery in HCC. Also we investigated the efficiency of inhibition of miR-
221 and restoration of miR-199a using chemically modified antimiR and mimics oligos 
alone and in combination of FDA approved chemotherapy agent “Sorafenib” in HCC cell 
lines and mouse model as well. 
5.1. Arresting the Oncogenic miR-221 by microRNA Sponge.  
 
MicroRNA sponges offers advantages to inhibit mature miRNA levels. One is the 
convenience of making dominant negative transgenics over knockouts, and the 
applicability to a broader range of model organisms and cell lines. In addition, many 
miRNAs have seed family members encoded at multiple distant loci; due to this functional 
redundancy, these miRNAs would have to be knocked out individually and the animals 
bred to generate the complete knockout strain(177). Sponges also offer advantages over 
chemically modified antisense oligonucleotide inhibitors. First, these antisense inhibitors 
CHAPTER 5 DISCUSSION 
 
appear to be specific for one miRNA as they depend upon extensive sequence 
complementarily beyond the seed region. Thus, to neutralize a family of miRNAs may 
require the delivery of a mixture of perfectly complementary oligonucleotides(177). In 
addition the risk of off-target gene silencing using microRNA Sponge is likely to be lower 
than synthetic oligonucleotide inhibitor(208). Since physiologic gene expression networks 
have evolved to accommodate the regulatory effects of endogenous miRNAs , the 
regulation of hundreds of targets in multiple pathways by miRNAs may reduce at the same 
time(34).  
In our construct, which named “miR-221sponge”, tandem arrayed binding sites for a 
mature microRNA 221 were inserted near to a reporter gene under the control of the strong 
promoter. The binding sites were designed to consist of a bulge (i.e., a series of 
mismatches adjacent to the miRNA seed region (nt 12-15), in order to prevent cleavage by 
Ago-2 and thus degradation of the sponge(177, 209). Instead, these bulges ideally enforce 
the stable binding and thus sequestration of the targeted miRNA complexes(15). We 
showed functionality of designed miR-221sponge through molecular assays following 
transient transfection of human cell lines. miR-221sponge resulted in significantly reduced 
miR-221 levels respect to control treatment. These observations supported by an increase 
in protein level of p27Kip1 ,a cell cycle regulatory factors have been implicated in human 
HCC. Duel luciferase reporter assay also validated the efficiency of miR-221sponge in 
inhibition of miR-221. The results described here exhibited sponge designed to inhibit 
miR-221 as a known oncomiRs are quite promising in modulating the aberration level of 
miR-221. 
So the concept of miRNA sponge was essentially more validated. However sponges are 
vector driven approaches. To provide a safeguard for gene therapy and the feasibility for a 
clinical application, efforts have been focused predominantly upon constructing liver-
targeted vector recently.  
Ebert et al. demonstrated the capability of sponges to de-repress endogenous targets in 
cultured cells, by reporting an up to 2.5-fold increase in a specific miR-20 target (E2F1) 
following transfection of the miR-20 sponge(185). Considering that maximal effects in 
Ebert et al.'s hands required transfection of high plasmid copy numbers, it remained 
unclear whether comparable efficacies can be obtained using viral delivery vectors, 
especially those based on typical low-copy integrating vectors, such as lentiviruses. The 
latter issue has been addressed by another group. Gentner et al.(2009) demonstrated an 
intriguing novel application of lentiviral sponges. They engineered recombinant 
CHAPTER 5 DISCUSSION 
 
lentiviruses to express sponges against miR-223, a highly abundant miRNA in U937 
monocytes. When co-transfected with a luciferase reporter regulated by miRNA binding 
sites in its 3′UTR, sponges effectively (nearly 50%) rescued reporter gene expression. 
Similarly, they reported successful de-repression of an endogenous miR-233 target. despite 
the success of Gentner et al.'s work, the general usefulness of lentiviruses to express 
miRNA sponges remained unclear, especially in an in vivo setting.  As pointed out by the 
authors, efficient de-repression of endogenous targets requires high vector copy numbers, 
which are, however, hard to achieve and maintain with integrating lentiviruses(210). 
Moreover, raising the number of integrants concurrently increases the risks of adverse 
insertional mutagenesis. While there is no doubt that lentiviruses hold enormous promise 
for a large number of gene therapy strategies, other efficient non-integrating viral vectors, 
such as adenovirus or AAV might ultimately be a better choice for miRNA sponge 
applications, particularly in vivo as reviewed by Grimm et al(2009)(15).  
The clinical translatability of such a relatively low efficacy, at the cost of high integration 
rates and associated risks of insertional mutagenesis in gene transfer by retroviruses, 
persuade us in providing a proof of concept of sponge transfer using other attractive viral 
delivery system. We picked up our sponge designed against  miR-221 on adeno and adeno-
associated virus(AAV).  
We proposed that equipping the engineered adeno-associated virus to sponge antisense 
miR-221 provide a tool for stable inhibition of miRNAs and guide further development of 
therapeutic strategies. rAAV are suited to mediate miRNA inhibitors because they can 
safely transduce a wide range of tissues and provide sustained level of gene expression. 
This system is used to introduce genes into cells for gene therapy studies(34, 198, 211). 
Compared to retro viral delivery systems, AAV carry substantially diminished risk of 
insertional mutagenesis since viral genomes persist primarily as episomes(212). Further, 
the availability of multiple AAV serotypes allows efficient targeting of many tissues of 
interest(211, 213). Finally, the general safety of AAV has been well documented, with 
clinical trials(214, 215). This study is the first to our knowledge that shows a miR-221 
Sponge delivered by AAV was effective at reducing endogenous miR-221 and altering the 
level of miR-221 target proteins. In addition miR-221Sponge mediate by rAAV reduced 
viable tumor cell and increased markers of apoptosis. 
In this study also we described a oncolytic rAd-based delivery for conditionally inhibition 
of endogenous miR-221.  
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Among Adenovirus vector, we selected an oncolytic adenovirus, with the property of 
replicating in and killing cancer cells. We selected a Conditionally Replicative 
Adenoviruses (CRAds), whose replication was controlled by miR-199, which has been 
recently developed by Callegari, et al;2013 (196). miR-199 is highly expressed in normal 
liver, while it is strongly down-regulated in essentially 100% of HCCs, making cancer 
cells, but not normal hepatocytes permissive to viral expression and replication. We 
proposed that equipping the engineered adenovirus to sponge antisense miR-221 can arrest 
miR-221 mainly in HCC cells. The Ad-199T-miR-221sponge was indeed able to replicate 
in HepG2 cells, but not in the HepG2-199 cells that express significant levels of miR-199. 
In the same experimental setting, we have shown that Ad-199T-miR-221sponge produced 
a significant reduction of miR-221 levels and a concomitant increase of the CDKN1B/p27 
gene, a miR-221 target, in comparison with control virus treatment.  
In conclusion Adenovirus, likely because of the high copy number that can achieve was 
more effective, but rAAV produced significant, albeit lower effects. rAAV effects could 
however persist for months and viral infections could be repeated in vivo without being 
inhibited by the immune response. 
In summary, while not tested, the viral vectors developed in this work are ready to in vivo 
testing. These viruses can be produced at high titer, they can induce miR-221 inhibition 
and re-expression of its targets, So they may potentially induce measurable anti-cancer 
activity. 
 
5.2. Restoration of miR-199a Providing AAV Delivery. 
 
The most widely used cancer model in studying miR-199a is liver cancer. More than 50% 
of HCC tissues and cells showed significant down-regulation of miR-199a-5p, with 
increased expression of the pro-invasion molecule DDR1. In addition, miR-199a-3p was 
shown to be a modulator of cell cycle. It sensitized the cells towards drug treatment 
through its target mTOR (128). Jia et al (2012) used Lentiviral vectors to study miR-199a 
functions in HCC cell lines. They found that the involvement of miR-199a in the 
pathogenesis of HCC was linked to the abnormal regulation of multiple target genes.  HIF-
1α was identified as a direct target that trough it miR-199a inhibited cell proliferation in 
both in vitro and in vivo assays(125). In the present study we tested the practicability of 
adeno associated virus for delivery and expression of miR-199a sequence. Adeno-
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associated virus stably express transgene, thereby can be useful tools to study gene 
functions and some are now being considered for clinical gene therapy applications(198). 
We showed that Recombinant adeno-associated viruses generated in this study , express 
high level miR-199a in HCC cell lines regards to controls. Cancerous features of HCC cell 
lines like viability and apoptosis affected by restoration of miR-199a through AAV 
delivery. Indeed AAV mediated inducing down-regulated miRNAs level can be a 
promising approach for getting through in molecular function of miRs. In addition, cell 
growth inhibition and apoptosis induction by miR-199a mediated AAV delivery represent 
great relevance due to its possible therapeutic potential.    
 
5.3. Investigation of Combined Anticancer Effects of AntimiR-
221/miR-199 and Sorafenib. 
 
HCC is a multi-factorial disease. Therefore, the expression of a large number of genes, 
proteins and other molecules from diverse cellular processes and pathways are altered in 
HCC. Hence, the use of a combination therapy that targets multiple different steps and 
pathways, rather than a single test or a set of tests, might be an appropriate strategy to 
combat human HCC(5).  
miRNAs that are capable of targeting many mRNAs simultaneously as well as using 
multikinase inhibitor sorafenib which affect most known molecular pathways associated 
with hepatocarcinogenesis can fit this bill perfectly. 
miRNAs are currently the most widely studied and can simultaneously repress hundreds of 
genes to directly influence the output of interconnected biological networks. Aberrant 
miRNA expression patterns have been described in various cancers and alteration in 
miRNA expression highly correlate with progression and prognosis of human malignant 
diseases. Although the use of synthetic inhibitor of miR-221 might be a promising 
approach to HCC therapies, it is assumed that single miRNA replacement or inhibitory 
therapy for a cancer will not be effective on every patient. Conceivably, a combination 
approach would have a broader spectrum of susceptible tumors and improved efficacy in 
patients(157). 
On the other hand, the discovery of targeted therapy with multi-tyrosine kinase inhibitors, 
such as sorafenib has been an important breakthrough for patients with advanced 
cancer(216). Sorafenib (Nexavar, BAY 43-9006) is a multikinase inhibitor which affect 
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most known molecular pathways associated with hepatocarcinogenesis include the 
Ras/Raf/MAP/ERK, the PI3K/Akt/mTOR, the Wnt/β-catenin and the JAK/STAT 
pathways(201). It  is the only FDA approved medication for treatment of this disease that 
has shown efficacy against a wide variety of tumors in preclinical models(217). In two 
recent phase III trials in patients with advanced HCC an overall survival benefit of three 
months compared to placebo was demonstrated(7, 218). Although these results are 
encouraging, the use of sorafenib is hampered by two phenomena. First of all, up to 80% 
of patients treated with sorafenib suffer from side effects. The most important grade 3 
adverse events include hand-foot syndrome, diarrhea, hypertension and fatigue(219, 220). 
In the SHARP trial 26% in the sorafenib arm needed dose reductions, 44% had short-term 
‘‘drug holidays’’ and 11% had to permanently discontinue the treatment due to drug-
related adverse events(7). The second phenomenon is that patients who initially respond to 
therapy eventually will show progression(216). Combination therapy with 
cisplatin/interferon/ doxorubicin/5-fluorouracil produced somewhat higher response rates 
than single agent, however, at the expense of significantly higher toxicity(5).  
Positive therapeutic outcomes achieved with sorafenib, as well as evidence that showed the 
effects of a modified AMO against miR-221 in reducing the number and size of HCC 
tumors in a miR-221 transgenic mouse model(176) and inhibition of the cell proliferation 
and cell cycle by restoration of miR-199a in HCC cells(221), lead us hypothesize that the 
combination of an miR-221 specific inhibitor or mimics miR-199a and sorafenib is a 
feasible way to improve the drug response. 
Herein, we assessed oncogenic effect of combining of antisense miR-221/mimic miR-199a 
oligos with sorafenib in two hepatocellular carcinoma cell lines, HepG2 and  Hep 3B. 
HepG2 come from 15years old male and hep3b come from 8 years od female. The first do 
not form tumor in mice, the last yes. Hep3B is p53 null while HepG2 has wild type p53. 
Hep3B have a higher metabolic rate than HepG2(Source of data: atcc cell line). In the 
present study, anti-cancer effects were assessed using viability and two different apoptosis 
assays that explored caspase3/7 or annexin V activity.  
We first conducted anti-proliferation and apoptosis analysis of sorafenib on both HCC cell 
lines. We demonstrated that sorafenib inhibited HCC cell growth and these effects 
correlate with dose-dependent induction in apoptosis. Our results in agreement with 
Fernando et al(217) indicated that sorafenib induce apoptosis through p53-dependent and 
independent pathway, since Hep3B cells show p53 deletion, whereas HepG2 are p53 wild 
type. However drug susceptibility was obviously different in HepG2 in comparison of 
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Hep3B cell lines, as HepG2 cell line showed saturation of apoptotic effect at lower dose. 
So IC50s of sorafenib were calculated in both cell lines. Results revealed that lower dose 
of sorafenib is needed to diminish the viability by 50% in HepG2 respect to Hep3B cell 
lines. Combination therapy with oligos (100nM) and sorafenib was conducted in HepG2 
and Hep3B cells in sorafenib dose near or lower than IC50 to show the synergic effect 
more feasible. we applied chemically modified antisense miRNA oligos against miR-
221(antimiR-221) and mimics miR-199a. Our data showed that antimiR-221 or miR-199a 
restoration sensitized HepG2 to sorafenib-induced cell death, indicating that combinational 
therapy of a miR-221 inhibitor/mimics miR-199a and sorafenib may be a good therapeutic 
approach to enhance current therapy. More than that, we found that the caspase3/7 activity 
of HepB3 was significantly increased with miR-221 inhibitor, suggesting that a saturation 
threshold was reached in these cell .So in spite of the apoptotic features were clearly 
showed the  efficiency of combination therapy, we did not succeed to show the synergistic 
effect of antimiR-221 and sorafenib in Hep3B through caspase3/7 activity assay. To verify 
the data of apoptosis, Annexin V/7-AAD staining by flow cytometry were performed. The 
result of Annexine activity was conversely in line with viability. Successful In vitro study 
in two different HCC cell line, resulted that apoptotic can be induced through p53-
dependent and independent pathways. 
miR-199a restoration also was tested in vivo by applying single administration of miR-
199a oligos and sorafenib as well as their combination. The test was done using miR-221 
transgenic (TG221) mouse which are predispose to develop HCC. We were successful to 
show the potency of miR-199 -based restoration therapy in parallel with sorafenib.  
In summary, antisense miR-221/mimics miR-199a strengthened the anti-cancer effect of 
sorafenib. These preliminary results warrant further investigation of combining miRNA 
therapeutics and traditional anticancer agents for selective, personalized medicine. 
 
5.4. Perspectives 
 
A critical conclusion is that stringent prohibition of miR-221 would be feasible through 
new technology called sponge as well as antisense microRNA oligos(AMO). Because 
miR-221 is increased in a number of solid tumors including pancreas(66), non–small cell 
lung cancer(100), glioblastoma(206), and thyroid cancer(61), optimizing a method to arrest  
miR-221 and to deliver them efficiently to the target tissues might be a useful approach to 
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target tumors besides HCC. Also positive anticancer effects of restoration of miR-199a in 
vitro and in vivo would open a new hope for developing a novel cancer therapeutic 
regimen. Indeed to better elucidate the molecular mechanisms of miR-221 and miR-199a 
and further investigate as a potential biomarker and a promising approach for HCC, 
additional animal-based experiments are needed.  
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